Characterization of ceramide synthases (Cers) in mammalian cells by Park, Hyejung
CHARACTERIZATION OF CERAMIDE SYNTHASES (CERS) IN 
MAMMALIAN CELLS 
 
 
 
 
 
 
 
 
 
 
A Dissertation 
Presented to 
The Academic Faculty 
 
 
 
 
by 
 
 
 
Hyejung Park 
 
 
 
 
In Partial Fulfillment 
of the Requirements for the Degree 
Doctor of Philosophy in the 
School of Biology 
 
 
 
 
 
 
 
Georgia Institute of Technology 
August 2009 
 
 
CHACTERIZATION OF CERAMIDE SYNTHASES (CERS) IN 
MAMMALIAN CELLS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Approved by:   
   
Dr. Alfred H. Merrill, Jr, Advisor 
School of Biology 
Georgia Institute of Technology 
 Dr. M. Cameron Sullards 
School of Chemistry and Biochemistry
Georgia Institute of Technology 
   
Dr. Marion B. Sewer 
School of Biology 
Georgia Institute of Technology 
 Dr. Yuhong Fan 
School of Biology 
Georgia Institute of Technology 
   
Dr. John Cairney 
School of Biology 
Georgia Institute of Technology 
  
   
  Date Approved:  [Mar. 26, 2009]  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
[This dissertation is dedicated to my husband, Philseok, and my family in Korea for their 
love and endless support during my Ph. D. study.] 
  
 
 
 
 
 
 iv 
ACKNOWLEDGEMENTS 
 
 I would like to express my sincere gratitude to my advisor, Professor Alfred H. 
Merrill, Jr., for his guidance, encouragement, and endless support and interest provided 
during the course of this research.  He has been my best source of inspiration and support.  
I am also deeply indebted to Dr. M. Cameron Sullards for the invaluable advice and 
support he has provided to make this research possible.  I would like to thank Professors 
Marion B. Sewer, John Cairney and Yuhong Fan for serving on my Ph. D. committee and 
for their discussions and insights. 
 I would like to thank all other fellow co-workers in Dr. Merrill’s group who 
contributed to this research: Ms. Elaine Wang, Ms. Kacee Sims, Mr. Samuel Kelly, Mr. 
Christopher Haynes, Ms. Rebecca Shaner, and Mr. Brent Portz. 
 My collaborators outside Georgia Tech who partially contributed to this research 
are also acknowledged: Professor Anthony H. Futerman at Weizmann Institute of Science, 
Israel, Dr. Alison Narin and Professor Kelly Moremen at University of Georgia, 
Professor Akemi Suzuki at Tokai University, Japan and Dr. Ronald T. Riley at USDA. 
 This research was financially supported by the NIH grant GM 69338 (Lipid 
Maps) and the NIH grant RR018502 for the Integrated Technology Resource for 
Biomedical Glycomics at the University of Georgia.   
 Finally, I would like to thank my family in Korea and my husband, Philseok, for 
their continuous support and encouragement.  Without them, this dissertation would not 
be possible. 
 
 
 v
TABLE OF CONTENTS 
Page 
ACKNOWLEDGEMENTS iv 
LIST OF TABLES x 
LIST OF FIGURES xi 
LIST OF SYMBOLS AND ABBREVIATIONS xiv 
SUMMARY xviii 
CHAPTER 
1 Introduction: Towards characterization of the mouse sphingolipidome. A survey 
of literature on mouse sphingolipid structure and function. 1 
1.1 Classification 1 
 1.1.1 Ceramide Backbone 2 
 1.1.2 Ceramide Synthases 2 
 1.1.3 Glycan Headgroups 5 
1.2 Distribution 6 
 1.2.1 Root Molecules: Precursors to six series in GSL biosynthesis 6 
 1.2.2 Ganglio-series [NeuAcα2-3Galβ1-4Glcβ1-1’Cer] 7 
 1.2.3 Lacto-series [Galβ1-3GlcNAcβ1-3Galβ1-4Glcβ1-1’Cer] 20 
 1.2.4 Neolacto-series [Galβ1-4GlcNAcβ1-3Galβ1-4Glcβ1-1’Cer] 24 
 1.2.5 Globo-series [Galα1-4Galβ1-4Glcβ1-1’Cer] 28 
 1.2.6 Isoglobo series GSLs [Galα1-3Galβ1-4Glcβ1-1’Cer] 36 
 1.2.7 Sulfated GSLs 36 
 1.2.8 Gala-series [Galα1-4Galβ1-1’Cer] 37 
 vi
 1.2.9 Sulfoglucuronyl-neolacto series  [HSO3-3GlcUβ1-3Galβ1-
4GlcNAcβ1-3Galβ1-4Glcβ1-1’Cer] and [HSO3-3GlcUβ1-3Galβ1-
4GlcNAcβ1-3Galβ1-4GlcNAcβ1-3Galβ1-4Glcβ1-1’Cer] 38 
 1.2.10 Psychosine, galactosylsphingosine 39 
1.3 Roles in development 39 
1.4 Roles in tumorigenesis 41 
1.5 Mouse models 44 
1.6 Future directions 45 
1.7 References 46 
2 Transcript profiling and metabolomic analysis of ceramide biosynthesis in mouse 
embryonic stem cells and embryonic bodies 52 
2.1 Introduction 52 
2.2 Experimental procedures 55 
 2.2.1 Growth and characterization of mESCs and EBs 55 
 2.2.2 Measurement of gene expression levels using quantitative RT-PCR 
(qRT-PCR) 56 
 2.2.3 Integration of gene expression data with Sphingo-GenMAPP 
pathway 57 
 2.2.4 Liquid Chromatography-Electrospray Ionization Tandem Mass 
Spectrometry (LC ESI-MS/MS) 57 
2.3 Results 60 
 2.3.1 Characterization of R1 mESCs and EBs 60 
 2.3.2 Differences in the expression of sphingolipid metabolism in R1 
mESCs and EBs using Sphingo-GenMAPP 61 
 2.3.3 Characterization of the Cer backbone species of R1 mESCs and EBs
 64 
 2.3.4 Analysis of the fatty acyl-CoA species in R1 mESCs and EBs 66 
 2.3.5 Characterization of the DHCer and Cer backbone subspecies of 
(DH)SL in R1 mESCs and EBs 66 
 vii
 2.3.6 Characterization of the DHCer and Cer backbone subspecies of 
(DH)SL in D3 mESCs and EBs 69 
2.4 Discussion 71 
2.5 References 76 
3 Characterization of ceramide synthase 2: Tissue distribution, substrate specificity 
and inhibition by sphingosine 1-phosphate 79 
3.1 Introduction 79 
3.2 Experimental procedures 80 
 3.2.1 Materials 81 
 3.2.2 Real-time qPCR 81 
 3.2.3 Short interfering RNA (siRNA) 82 
 3.2.4 Cell culture and transfection 85 
 3.2.5 LC ESI-MS/MS 85 
 3.2.6 CerS assay 86 
 3.2.7 Immunofluorescence 86 
3.3 Results 87 
 3.3.1 CerS expression in mouse tissues 87 
 3.3.2 Acyl-CoA specificity and intercellular localization of CerS2 91 
 3.3.3 Relationship between CerS mRNA Expression and Ceramide N-
Acyl Chain Composition 96 
 3.3.4 Inhibition of CerS2 Activity by S1P 99 
3.4 Discussion 107 
3.5 References 112 
4 Ceramide synthase inhibition by fumonisin B1 causes accumulation of 1-
deoxysphinganine: A novel categories of bioactive 1-deoxysphingoid bases and 1-
deoxydihydroceramides biosynthesized by mammalian cell lines and animals 
 114 
4.1 Introduction 114 
 viii
4.2 Experimental procedures 116 
 4.2.1 Materials 116 
 4.2.2 Cell culture 117 
 4.2.3 Sphingolipid Extraction and Analysis 119 
 4.2.4 Analysis of Stable Isotope-labeled Sphingoid Bases using L-[U-
13C]Alanine and L-[U-13C]Serine 122 
 4.2.5 Analysis of 1-DeoxySa and Metabolites in LY-B and LY-B-LCB1 
Cells 122 
 4.2.6 Effect of Sa and 1-DeoxySa on Cell Growth, Accumulation of 
Sphingoid Bases, Sphingoid Base 1-Phosphates, Cer, and 1-DeoxyDHCer
 123 
 4.2.7 Analysis of 1-DeoxySa in Mice Fed FB1 124 
 4.2.8 Synthesis of N-Acyl-1-Deoxysphinganine 124 
 4.2.9 Analysis of 1-DeoxySa in SPT1/2 cells with Amino Acid 
Supplementation 125 
 4.2.10 Analysis of 1-DeoxySa in SPT1/2 cells with 3-Phosphoglycerate 
dehydrogenase (PHGDH) and 3-Phosphoserine phosphatase (PSPH) 
siRNAs 126 
 
4.3 Results 126 
 4.3.1 FB1 Elevates Sa and a Mystery Peak in Cells 126 
 4.3.2 Evidence that the Mystery Peak Is an Unidentified Sphingoid Base 
 129 
 4.3.3 Identification of the Novel Sphingoid Base as 1-DeoxySa (m18:0)
 131 
 4.3.4 Biosynthesis of 1-DeoxySa from [13C]Alanine by SPT 135 
 4.3.5 Endogenous 1-DeoxyDHCer and Acylation of Exogenously Added 
1-DeoxySa in LLC-PK1 Cells 142 
 4.3.6 Cytotoxicity of 1-DeoxySa 144 
 4.3.7 Analysis of 1-DeoxySa in Liver and Kidneys of Mice Fed FB1 148 
 ix
 4.3.8 Validation of LC ESI-MS/MS Conditions for N-Acyl-1-
Deoxysphinganine 150 
 4.3.9 Re-examination of the Biosynthesis of Novel Sphingoid Bases upon 
Supplementation of the Culture Medium with Different Amino Acids 155 
 4.3.10 The Types and Amounts of the Sphingoid Bases that Are Produced 
by Can Be Affected Substantially by Amino Acid Supplementation 159 
 4.3.11 Analysis of 1-DeoxySa in SPT1/2 cells with Knock Down of Serine 
Metabolism 166 
4.4 Discussion 169 
4.5 References 175 
5 Conclusions 178 
5.1 References 180 
 
LIST OF PUBLICATIONS 181 
 x
LIST OF TABLES 
Page 
Table 1.1: Functions of GSLs in the mouse 6 
Table 1.2: Functions of GSLs in tumors (Hakomori 2000) 41 
Table 3.1: Primers used in the current study 83 
Table 3.2: Levels of ceramide, HexCer and SM are shown for five different tissues. This 
data is presented in Fig. 3.7 as a percent distribution, and are from three 
triplicate analyses from two animals. 99 
Table 3.3: CerS2 has genomic features characteristic of a housekeeping gene 108 
Table 4.1: API 3000 Mass Spectrometer Settings for ceramide, 1-deoxydihydrceramide 
and 1-desoxymethyldihydroceramide 152 
Table 4.2: ABI 4000 Mass Spectrometer Settings for Long Chain Bases and 1-deoxy-
sphingoid bases 159 
 
 
 xi
LIST OF FIGURES 
Page 
Figure 1.1: De novo biosynthesis of sphingolipid metabolism. Illustration of early steps of 
sphingolipid metabolism using a modified KEGG pathway 
(www.sphingomap.org) 4 
Figure 1.2: Glycosphingolipidomic role in defining tumor potency (Hakomori 2002) 40 
Figure 1.3: Glycosphingolipidomic role in defining tumor potency (Hakomori 2002) 43 
Figure 2.1: Depiction of the early steps of sphingolipid biosynthesis using a modified 
KEGG pathway scheme (Sphingo-GenMAPP) to facilitate visualization of 
differences in gene expression in by R1 mESCs and EBs 54 
Figure 2.2: Relative transcript abundance of CerS (Lass) genes (A) and fatty acyl-CoA 
elongase (Elovl) genes (B) by qRT-PCR for R1 mouse embryonic stem cells 
and day 6 EBs 63 
Figure 2.3: Ceramide and fatty acyl-CoA composition of R1 mouse embryonic stem cells 
at different timepoints during EB formation 65 
Figure 2.4: Subspecies distributions of (dihydro)ceramides, (dihydro)ceramide 
monohexoses and (dihydro)sphingomyelins of R1 mouse embryonic stem cells 
and day 6 embryoid bodies 68 
Figure 2.5: Subspecies distributions of (dihydro)ceramides, (dihydro)ceramide 
monohexoses and (dihydro)sphingomyelins of D3 mouse embryonic stem cells 
and day 6 embryoid bodies 70 
Figure 2.6: Sphingolipid subspecies composition of D3 mouse embryonic stem cells at 
different timepoints during ES formation 73 
Figure 2.7: Sphingolipid subspecies composition of R1 mouse embryonic stem cells at 
different timepoints during ES formation 74 
Figure 3.1: qPCR assays are linear over a wide range of RNA and cDNA concentrations 
 84 
Figure 3.2: qPCR reactions for CerS mRNA are highly sensitivity and linear over 8-10 
orders of magnitude 88 
Figure 3.3: CerS2 is ubiquitously expressed and is highly abundant in mouse tissues 90 
Figure 3.4: Substrate specificity of CerS2 toward acyl-CoAs 93 
 xii
Figure 3.5: Effect of siRNA on mRNA expression, ceramide synthesis, and ceramide 
levels 94 
Figure 3.6: CerS2 is localized to the endoplasmic reticulum 95 
Figure 3.7: mRNA expression levels for CerS1 to -6 compared with the N-acyl chain 
distribution of ceramides, SM, and HexCer in five mouse tissues 98 
Figure 3.8: Ceramide profiles in livers derived from wild type mice (+/+, blue) and CerS2 
null mice (-/-, black) at ages (days)  102 
Figure 3.9: Ceramide monohexoses profiles in livers derived from wild type mice (+/+, 
blue) and CerS2 null mice (-/-, black) at ages (days)  103 
Figure 3.10: Sphingomyelin profiles in livers derived from wild type mice (+/+, blue) and 
CerS2 null mice (-/-, black) at ages (days)  104 
Figure 3.11: Sphingoid bases (sphingosine and sphinganine) profiles in livers derived 
from wild type mice (+/+, blue) and CerS2 null mice (-/-, black) at ages (days)
 105 
Figure 3.12: Fatty acyl-CoA profiles in livers derived from wild type mice (+/+, blue) 
and CerS2 null mice (-/-, black) at ages (days) 106 
Figure 4.1: Representative chromatograms of lipid extracts from confluent cultures of 
LLC-PK1 cells treated with FB1 and analyzed by HPLC with fluorescence 
detection of the free sphingoid bases as the OPA derivatives using C20-Sa as 
an internal standard 128 
Figure 4.2: Changes in free Sa (d18:0) and the unidentified sphingoid base (UnID) in 
confluent cultures of LLC-PK1 cells treated with FB1 and/or myriocin 130 
Figure 4.3: Liquid chromatography of LLC-PK1 cell extracts after 24 h (A) and 120 h (B) 
of treatment with FB1 with monitoring for Sa and a novel sphingoid base by 
electrospray ionization tandem mass spectrometry 133 
Figure 4.4: Comparison of the MS3 spectra for synthetic 1-deoxySa (A) and the deoxySa 
isolated from LLC-PK1 cell extracts (B) using the method of Riley et al. 134 
Figure 4.5: Structures of Sa and 1-deoxySa and a scheme for the biosynthesis of 1-
deoxySa and its accumulation in cells exposed to FB1. Also shown are the 
known sites of inhibition by FB1 and myriocin 136 
Figure 4.6: Incorporation of L-[U-13C]alanine (A) and L-[U-13C]serine precursors (B) 
into the 1-deoxySa (m18:0), Sa (d18:0), and Sa1P (d18:0-P) in Vero cells 
treated with 35 µM FB1 for 48 h and grown in medium containing increasing 
concentrations of either L-[U-13C]alanine- or L-[U-13C]serine (100 µM to 500 
µM) 138 
 xiii
Figure 4.7: Absence of 1-deoxySa biosynthesis by LY-B cells and restoration of its 
formation in LY-B-LCB1 cells 141 
Figure 4.8: Endogenous N-acyl-sphingoid bases in LLC-PK1 cells and after incubation of 
the cells with exogenously added 1-deoxySa with or without FB1 143 
Figure 4.9: Effects of 1-deoxySa on LLC-PK1 and DU-145 cells 145 
Figure 4.10: Accumulation of Sa (A and D), Sa1P (B and E), 1-deoxySa (C and F), and 
decrease in ceramide (G) and change in 1-deoxydihydroceramide (H) levels in 
LLC-PK1 cells treated as described in Fig. 4. 9 but only at the 10 µM 
concentration of Sa and 1-deoxySa (A–C) or in combination with 50 µM FB1 
(D–F) 147 
Figure 4.11: Accumulation of Sa (d18:0, black bars) and 1-deoxySa (m18:0, gray bars) 
in liver (upper) and kidneys (lower) of male P53N5-W mice fed a modified 
AIN-76A diet containing 0 ppm (Control) or 50 ppm FB1 for 6 months 149 
Figure 4.12: Signal response for ceramides using LC ESI-MS/MS 153 
Figure 4.13: Signal response for 1-deoxydihydroceramides using LC ESI-MS/MS 154 
Figure 4.14: Re-examination of the biosynthesis of novel sphingoid bases upon 
supplementation of the culture medium with different amino acids 157 
Figure 4.14: Re-examination of the biosynthesis of novel sphingoid bases upon 
supplementation of the culture medium with different amino acids (Continued)
 158 
Figure 4.15: Evaluation of the biosynthesis of novel sphingoid bases upon 
supplementation of the culture medium with different amino acids 161 
Figure 4.15: Evaluation of the biosynthesis of novel sphingoid bases upon 
supplementation of the culture medium with different amino acids (Continued)
 162 
Figure 4.16: N-acyl-sphingoid base biosynthesis by SPT1/2 cells with amino acid 
supplementations. L-serine, L-alanine and L-glycine (each has 10 mM 
concentration) were incorporated [13C]palmitate into the sphingoid base 
backbone (labeled 13C-base ) 164 
Figure 4.17: N-acyl-sphingoid base biosynthesis by SPT1/2 cells with amino acid 
supplementations. L-serine, L-alanine and L-glycine (each has 10 mM 
concentration) were incorporated into both the sphingoid base and fatty acid 
(labeled 13C-base and fatty acid) 165 
 xiv
Figure 4.18: Effect of double knockdown by 3-phosphoglycerate dehydrogenase 
(PHGDH) and 3-Phosphoserine phosphatase (PSPH) siRNAs on 1-deoxySa 
synthesis 168 
Figure 4.19: The speculation of correlation between amino acid synthesis and 
sphingolipid biosynthesis 174 
 
 
 
 
 
 
 
 
 
 
 
 
 xv
LIST OF SYMBOLS AND ABBREVIATIONS 
 
SL  Sphingolipid 
GSL  Glycosphingolipid 
Cer  Ceramide 
CerS  Ceramide Synthase 
SPT  Serine Palmitoyltransferase 
3-ketoSa  3-Ketosphinganine 
Sa  Sphinganine 
So  Sphingosine 
SaP  Sphinganine 1-Phosphate 
SoP  Sphingosine 1-Phosphate 
DHCer  Dihydroceramide 
SM  Sphingomyelin 
DHSM  Dihydrosphingomyelin 
GlcCer  Glucosylceramide 
DHGlcCer Dihydroglucosylceramide 
GalCer  Galactosylceramide 
DHGalCer Dihydrogalactosylceramide 
LacCer  Lactosylceramide 
DHLacCer Dihydrolactosylceramide 
ST  Sulfatide 
DHST  Dihydrosulfatide 
CerP  Ceramide 1-Phosphate 
DHCerP  Dihydroceramide 1-Phosphate 
 xvi
SMase  Sphingomyelinase 
SMS  Sphingomyelin Synthase 
ASAH  Ceramidase 
SPHK  Sphingosine Kinase 
CerK  Ceramide Kinase 
CERT  Ceramide Transporter 
DES  Ceramide Desaturase 
EP  Ethanolamine Phosphate 
C16:0al  Hexadecanal 
C16:1al  Hexadecenal 
NKT Cells Natural Killer T Cells 
NeuAc  N-Acetyl-neuraminic acid 
NeuGc  N-Glycolylneuraminic acid 
ER  Endoplasmic Reticulum 
Fuc  Fucose 
GlcNAc  N-Acetylglucosamine 
GalNAc  N-Acetylgalactosamine 
Hex A  β-Hexosaminidase A 
Chol-1  Cholinergic nerve-specific molecules 
MAG  Myelin-Associated Glycoprotein 
SSEA  Stage-Specific Embryonic Antigen 
iGb3S  Isoglobotrihexosylceramide Synthase 
GlcU  Glucuronic Acid 
SGGL  Sulfoglucuronylglycolipid 
ES  Embryonic Stem 
 xvii
EC  Embryonic Carcinoma 
EGF  Epidermal Growth Factor 
VEGF  Vascular Endothelial Growth Factor 
CGT  Ceramide Galactosyltransferase 
GST  Glucosylceramide Synthase 
KEGG  Kyoto Encyclopedia of Genes and Genomes 
mESCs  Mouse Embryonic Stem Cells 
EBs  Embryoid Bodies 
PBS  Phosphate Buffered Saline 
LIF  Leukemia Inhibitory Factor 
qRT-PCR  quantitative Real Time-Polymerase Chain Reaction 
RPL4  Ribosomal Protein L4 
GenMAPP Gene MicroArray Pathway Profiler 
LC ESI-MS/MS Liquid Chromatography Electrospray Ionization-Tandem Mass 
Spectrometry 
IS  Internal Standard 
zfp42  Zinc Finger Protein 42 
GBX2  Gastrulation Brain Homeobox 
Nanog  Nanog Homeobox 
Gsc  Goosecoid 
Zic1  Zinc Finger Protein of the Celebellum 1 
Sox17  SRY-box Containing Gene 17 
Afp  Alpha Fetoprotein 
Gata6  GATA Binding Protein 6 
Elovl  Fatty Acyl-CoA Elongase 
CMH  Ceramide Monohexose 
 xviii
DHCMH  Dihydroceramide Monohexose 
siRNA  Short Interfering RNA 
Hek 293 cells Human Embryonic Kidney Cells 
GAPDH  Glyceraldehyde-3-Phosphate Dehydrogenase 
Elovl  Fatty acyl-CoA elongase 
MitoTracker Mitochondria-specific dye 
Protein disulfide isomerase Endoplasmic reticulum marker 
FB  Fumonisins 
FB1  Fumonisin B1 
OPA  Ortho-Phthalaldehyde 
LC  Liquid Chromatography 
1-DeoxySa 1-Deoxysphinganine 
1-DesoxyMeSa 1-Desoxymethylsphinganine 
1-DeoxyDHCer 1-Deoxydihydroceramide 
1-DesoxyMeDHCer 1-Desoxymethyldihydroceramide 
d18:0  sphinganine 
m18:0  1-Deoxysphinganine 
d18:0-P  Sphinganine 1-Phosphate 
LLC-PK1 Cells Pig Kidney Epithelial Cells 
Vero cells African Green Monkey Kidney Cells 
DU-145 Cells Human Prostate Cancer Cells 
MEM  Minimal Essential Medium 
DMEM  Dulbecco’s Modified Eagle’s Medium 
UnID  Unidentified Sphingoid Base 
HSN1  Human Sensory Neuropathy Type 1 
 xix
CHO Cells Chinese Hamster Ovary Cells 
PHGDH  3-Phosphoglycerate Dehydrogenase 
PSPH  3-Phosphoserine Phosphatase 
S.D.  Standard Deviation 
WT  Wild Type 
 xx
SUMMARY 
 
This thesis describes the characterization of ceramide (Cer) biosynthesis by 
mammalian cells.  The possibility that Cer undergo developmental changes was explored 
using mouse embryonic stem cells versus embryoid bodies by analysis of the Cer 
subspecies by liquid chromatography, electrospray ionization-tandem mass spectrometry 
(LC ESI-MS/MS) and of the transcript levels for enzymes involved in Cer biosynthesis 
by qRT-PCR.  Cer of embroid bodies had higher proportions of very-long-chain fatty 
acids, which correlated with the relative expression of mRNA for the respective Cer 
synthases (CerS) and fatty acyl-CoA elongases, as well as changes in the fatty acyl-
CoA’s of the cells.  Therefore, it is clear that Cer subspecies change during 
embryogenesis, possibly for functionally important reasons.  One CerS isoform, CerS2, 
was studied further because it has the broadest tissue distribution and a remarkable fatty 
acyl-CoA specificity, utilizing longer acyl-chain CoAs (C20–C26) in vitro. The fatty acid 
chain selectivity was refined by analysis of the Cer from livers from CerS2 null mice, 
which displayed very little Cer with fatty acyl chains with 24 + 2 carbons.  Another 
interesting structural variation was discovered in studies of cells treated with fumonisin 
B1 (FB1), which inhibits CerS.  Under these conditions, cells in culture and animals 
accumulate substantial amounts of a novel sphingoid base that was identified as 1-
deoxysphinganine. This compound arises from utilization of L-alanine instead of L-serine 
by serine palmitoyltransferase (SPT) based on the inability of LYB cells, which lack SPT, 
to make 1-deoxysphinganine.  In the absence of FB1, 1-deoxysphinganine is primarily 
acylated to 1-deoxydihydroceramides.  These are an underappreciated category of 
 xxi
bioactive sphingoid bases and “ceramides” that might play important roles in cell 
regulation and disease.  In summary, cells contain a wide variety of Cer subspecies that 
are determined by changes in expression of CerS, enzymes that produce co-substrates 
(such as fatty acyl-CoAs), and the types of amino acids utilized by SPT, the initial 
enzyme of de novo sphingolipid biosynthesis.  One can envision how these changes 
might impact membranes structure as well as signaling by this family of highly bioactive 
compounds. 
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CHAPTER 1 
INTRODUCTION: 
TOWARDS CHARACTERIZATION OF THE MOUSE 
SPHINGOLIPIDOME. A SURVEY OF LITERATURE ON MOUSE 
SPHINGOLIPID STRUCTURE AND FUNCTION. 
This review provides a template to trace the biosynthesis of glycosphingolipids 
(GSLs) across various murine tissues and organs. The abbreviations and symbols for 
carbohydrates and lipids follow the recommendations of the IUPAC/IUBMB 
Commission of Biochemical Nomenclature (1). 
Considering its resemblance to human cell behavior, murine systems are one of 
the most analyzed in sphingolipidomic biology. GSLs mediate crucial aspects of the 
differentiation, growth and development of mouse tissue beginning at the embryonic 
stage, and are integral in crucial cellular process that include signaling, trafficking, and 
cell-cell interactions. As a result, tracing the catabolic pathways of the molecules in their 
native tissues and describing their functions in the cell would provide an important tool in 
further analysis. This review provides this tool by survey the known 
glycosphingolipidomic pathways within a mouse model. 
 
1.1   Classification 
GSLs are characterized by a monosaccharide attached directly to a ceramide unit. 
Each of these units can be extended by the stepwise addition of more monosaccharides. 
 
 2
1.1.1 Ceramide Backbone 
Heterogeneity in sphingolipidomic structure can be seen in differences in the acyl 
chain length of the fatty acid attached to sphingosine (C14 - C24) (2), the degrees of 
saturation (C4 and C5) (3), hydroxylation (C4 or C6) (4), methyl branches at ω-1 (iso), 
ω-2 (anti-iso) and other positions (5), and the degrees of unsaturation at other sites along 
the chain (6). The bases are abbreviated by defining (in order of appearance) the number 
of hydroxyl groups (d for di- and t for tri-hydroxyl), chain length, and the number of 
double bonds (7). Ceramide (Cer) as a sphingoid base is an N-acylated fatty acid that is 
mostly saturated, and is described by either the presence, or the absence of a hydroxyl 
group at the α, or the ω carbon (8). As mentioned earlier, it contains a glycan as a polar 
headgroup in GSLs.  
 
1.1.2 Ceramide synthases 
Ceramide synthases (CerS) are the enzymes that are responsible for the acylation 
of sphingoid bases through the de novo biosynthetic pathway (9,10). Early studies 
detected CerS activity in microsomal fractions, and the enzyme was shown to utilize a 
variety of fatty acyl-CoAs although some specificity toward certain CoAs was recognized 
(11). CerS activity was later localized to the cytoplasmic leaflet of the endoplasmic 
reticulum (ER) (12,13). The first evidence for specific functional roles of mammalian 
CerS gene was obtained upon overexpression of CerS1 (formerly known as UOG1), 
which resulted in a selective increase in C18-ceramide in mammalian cells (14). CerS4 
(TRH1) and CerS5 (TRH4) were subsequently shown to selectively utilize C18/20 and 
C16 acyl-CoAs, respectively (15), CerS6 to produce shorter acyl chain ceramides (C14 
 3
and C16)(16), and CerS3 to produce C18- and C24-ceramides (17), although the 
surprisingly high levels of C18-ceramide synthesis are at variance with other analyses. 
CerS2 has the broad fatty acyl-CoA specificity (C20-C26) and tissue distribution (18). 
Verification that mammalian CerS proteins are bona fide ceramide synthases, rather than 
regulators of endogenous ceramide synthases, was obtained when purified CerS was 
shown to possess CerS activity (19). Together with the CerS activity of the purified 
Lag1-Lac1-Lip1 complex in yeast (20), this supports the concept that CerS proteins are 
genuine CerS, with each mammalian protein utilizing a relatively restricted subset of 
fatty acyl-CoAs. It is assumed that the six known mammalian CerS proteins account for 
the synthesis of all known ceramides, but the possibility cannot be excluded that some 
other proteins, such as ceramidases (21), might also contribute to the synthesis of 
(DH)Cer with restricted fatty acid composition. 
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Figure 1.1. De novo biosynthesis of sphingolipid metabolism. Illustration of early steps of 
sphingolipid metabolism using a modified KEGG pathway (www.sphingomap.org). The 
sphingolipid metabolites and genes (with the gene abbreviations shown in boxes, or 
enzyme names where gene names are ambiguous) are given for the condensation of 
serine and palmitoyl-CoA to form 3-ketosphinganine (3-ketoSa) by serine 
palmitoyltransferase, which is reduced to sphinganine (Sa), acylated to dihydroceramides, 
DHCer, by (DH)Cer synthases, and incorporated into more complex DH-sphingolipids 
(the 1-phosphate, DHCerP, sphingomyelins, DHSM, glucosylceramides, DHGlcCer, 
galactosylceramides, DHGalCer, lactosylceramides, DHLacCer, and sulfatides (DHST), 
or desaturated to Cer followed by headgroup addition. Also included are a number of the 
catabolic genes, e.g., sphingomyelinases, SMases, ceramidases, ASAH, sphingosine 
kinases, SphK, for the formation of sphinganine 1-phosphate (Sa1P) and sphingosine 1-
phosphate (So1P), and phosphatases for the reverse reaction and the lyase that cleaves 
sphingoid base 1-phosphates to ethanolamine phosphate (EP), hexadecanal (C16:0al) and 
hexadecenal (C16:1al). 
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1.1.3 Glycan Headgroups 
Galactosylceramide (Galβ1-1’Cer, or Gal-Cer), glucosylceramide (Glcβ1-1’Cer, 
or Glc-Cer), and lactosylceramide (Galβ1-4Glcβ1-1’Cer, or Lac-Cer) are primary in GSL 
biosynthesis, and serve as branch points for six families as defined by their core 
structures. While Lac-Cer itself stems off of Glc-Cer and leads to globo-series (Galα1-
4Galβ1-4Glcβ1-1’Cer), ganglio-series (NeuAcα2-3Galβ1-4Glcβ1-1’Cer), lacto-series 
(Galβ1-3GlcNAcβ1-3Galβ1-4Glcβ1-1’Cer), and neolacto-series (Galβ1-4GlcNAcβ1-
3Galβ1-4Glcβ1-1’Cer), Gal-Cer leads to the gala-series (Galα1-4Galβ1-1’Cer). GlcCer 
also forms the sulfoglucuronyl-neolacto series which contains a terminal sulfated 
glucuronic acid. Either of the molecules in the aforementioned series can also be sulfated 
and are discussed in a separate section herein. It must be noted that the root molecules are 
neutral and contain a β-glycosidic linkage to ceramide (7). 
These differences in the ceramide and glycan structure are cell-specific and depend 
on which stage of development the cell is at (22). For instance, the ceramide 
galactosyltransferase that synthesizes Gal-Cer shows a preference for hydroxy fatty-acid-
containing ceramides which are prevalent in the brain. As a result, Gal-Cer is mainly 
found in neuronal tissues. GSLs contribute to the structure of the outer leaflet of most cell 
membranes. The molar ratio of these molecules relative to the other major membrane 
lipids (phospholipids, cholesterol, and glycerolipids) varies from being minor (e.g., <5% 
in erythrocytes) to being a very major component (e.g., 30% of the total lipids in neuronal 
plasma membranes) (7,23).  
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Table 1.1. Functions of GSLs in the mouse 
Glycosphingolipids 
Receptors: Microbial exotoxins and adhesions 
Tumor-associated developmentally regulated antigens 
Allogenic antigens: A1A2BH, Lewis, P1P2, I/i 
Modulators of: Growth factor/hormone receptor, Function ? 
tyrosine kinase 
Cell adhesion mediators: Lectins (galectins, selectins), 
Carbohydrates (carbohydrate- carbohydrate interaction) 
Initiators of signal transduction through GSD (GSL 
signaling domain) 
 
1.2 Distribution 
1.2.1 Root Molecules: Precursors to six series in GSL biosynthesis 
Galactosylceramide [Galβ1-1’Cer] 
Owing to its initial discovery neuronal tissues, galactosylceramide is also called 
cerebroside. This can be located in the murine adrenal gland (24), and in the erythrocytes 
of C3H/He and CDF1 inbred mouse strains (25). α-GalCer is involved in the mouse CD1-
mediated stimulation of NKT cells, and does not require either antigen processing or 
endosomal uptake to be presented by mCD1 (26).  
 
Glucosylceramide [Glcβ1-1’Cer] 
Like Gal-Cer, this cerebroside can also be found in the adrenal gland  (24) in 
normal mice and in the erythrocytes of C3H/He and CDF1 inbred mouse strains (25). 
However, Glc-Cer also appears to play a role during development by being present in 
thymocytes in mice that are 1 to 30 weeks of age. This might account for its presence in 
murine myelogenous leukemias (27), since molecules that are vital during embryogenesis 
also account for tumorigenesis. It is also present in the murine lung (28) and uterus (29).   
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Lactosylceramide [Galβ1-4Glcβ1-1’Cer] 
Lac-Cer, or cytolipin H also plays a role in both embryogenesis and tumorigenesis 
by being present in thymocytes from mice that are 1 to 30 weeks of age and in murine 
myelogenous leukemias (27). It locates in the mouse lung (28), uterus (29) and adrenal 
gland (24) in a manner that is similar to its precursor, glucosylceramide. However, this 
molecule further translocates to muscle tissue in mice (30).  
 
 
1.2.2 Ganglio-series [NeuAcα2-3Galβ1-4Glcβ1-1’Cer] 
First discovered and predominant in nerve ganglions (hence the name), 
gangliosides are present in all cells in mice. All molecules in this series contain one or 
more subunits of an acidic monosaccharide called sialic acid, which can have acetyl (N-
acetyl-neuraminic acid, NeuAc), or glycolyl (N-glycolylneuraminic acid, NeuGc) groups 
attached commonly at the C5 position. Sialic acids latch on to the main glycolipid 
structure via an α2-3, or an α2-6 glycosidic linkage. A chain forms when subsequent acid 
residues attach to the former via an α2-8 glycosidic linkage. 
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NeuAc-containing gangliosides are especially present in E-10 and E-11 mouse 
embryos. These also play major roles in tumorigenesis. Aberrant ganglio-series 
glycolipids that are neutral can be found in murine myelogenous leukemias (27).  
 
Sialosylcerebroside GM4 [NeuAcα2-3Galβ1-1’Cer] 
A departure from the other sialic acid-containing GSLs, sialosylcerebroside 
contains galactosylceramide as the root structure instead of Glc-Cer. It has 
immunosuppressive properties and is useful in probing which elements of ganglioside 
structure are critical to their biological activity (31). Moreover, it has been used to 
examine the binding specificities of the sialoadhesin family of I-type lectins (32). Besides 
being predominant in the mouse brain, GM4 is present in the erythrocytes of C3H/He and 
CDF1 inbred mouse strains (25) alike its precursor Gal-Cer.  
 
1.2.2.1 o-series  
Gangliotriaosylceramide [GalNAcβ1-4Galβ1-4Glcβ1-1’Cer]  
Also known as GA2, asialo-GM2, and Gg3-Cer, gangliotriaosylceramide is 
present in the alveolar epithelium of the murine lung (28) and in low metastatic (Eb) 
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potential cells (33). It is a tumor-associated antigen and has been shown to be present in 
murine L5178Y lymphoma (34) and in the murine Lewis lung carcinoma cell line LL2. 
Moreover, it is also present in the tissue of mice carrying the Tay Sachs' disease (35) and 
as a result, is termed the Tay-Sachs globoside. This and the subsequent molecule asialo-
GM1 are exceptions in that they are part of the ganglio-series, yet contain no sialic acid 
residues. 
 
Gangliotetraosylceramide [Galβ1-3GalNAcβ1-4Galβ1-4Glcβ1-1’Cer] 
Gangliotetraosylceramide, a differentiation antigen in the mouse, is present in 
myelogenous leukemias (27). In addition to the alveolar epithelium of the murine lung 
(28) and in low metastatic (Eb) potential cells (33) where it is synthesized from GA2, 
gangliotetrasylceramide (GA1, Gg4Cer, asialo-GM1, AM1) is also present in epithelial 
cells of the small intestine (36), splenic T lymphocytes, uterus (29), thymus, and in 
peritoneal macrophages.  
 
Monosialoganglioside GM1b [NeuAcα2-3Galβ1-3GalNAcβ1-4Galβ1-4Glcβ1-1’Cer] 
GM1b, or cis GM1 is a potent neuronal ligand for myelin-associated 
glycoproteins (37). It is a tumor ganglioside (38), and is present in low metastatic (Eb) 
potential cells (33) and peritoneal macrophages like its precursor. However, GM1b is also 
present in the mouse spleen (39) where it probably translocates to after being synthesized 
from GA1 in the intestine. Both NeuAc and NeuGc containing GM1b are present in the 
spleen, myelogenous leukemias (27) and YAC-1 murine lymphoma cells (40). Immature 
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T cells also contain this molecule. GM1b branches to three other molecules: GalNAc-
GM1b, GD1c and GD1α. 
 
Monosialoganglioside GalNAc-GM1b [GalNAcβ1-4(NeuAcα2-3)Galβ1-3GalNAcβ1-
4Galβ1-4Glcβ1-1’Cer] 
The attachment of a GalNAc via a β1-4 glycosidic linkage to GM1b does not 
change its location. These remain in the mouse spleen (41), and those containing both 
NeuGc and NeuAc sialic acids are present in myelogenous leukemias (27) and YAC-1 
murine lymphoma cells (40). 
Subsequent molecules such as Galβ1-3GalNAcβ1-4(NeuGcα2-3)Galβ1-
3GalNAcβ1-4Galβ1-4Glcβ1-1’Cer are also present in the mouse spleen (41). 
 
Monosialoganglioside GD1c [NeuAcα2-8NeuAcα2-3Galβ1-3GalNAcβ1-4Galβ1-4Glcβ1-
1’Cer] 
GD1c is also responsible for tumors like its precursor, GM1b. It is also present in 
spontaneous murine thymoma (42) and GD1c (NeuGc-NeuGc) can be found in mouse 
thymocytes and splenocytes (43). 
 
Monosialoganglioside GD1α [NeuAcα2-3Galβ1-3(NeuAcα2-6)GalNAcβ1-4Galβ1-
4Glcβ1-1’Cer] 
GD1α is present in low metastatic (Eb) potential cells (33) and in the lactating 
mammary gland of DDD and ICR mice (39,44). Macrophages also contain this molecule. 
This can be explained by the existence of its precursor GM1b in immature T cells. GD1α 
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is also a differentiation-resistant clone of mouse myeloid leukemia cells M1-R1 (45). 
Present as an accumulated structure in the proximal dendrites and cell bodies of Purkinje 
cells in murine cerebellum (46). 
 
1.2.2.2 a-series 
The a-series of gangliosides are reported as cholinergic nerve-specific molecules 
(Chol-1) (47,48), or as molecules that bind to myelin-associated glycoproteins in vitro 
(49). Consequently, they play critical roles in the interaction and communication between 
neuronal cells and their supportive cells (50). 
 
Monosialoganglioside GM3 [NeuAcα2-3Galβ1-4Glcβ1-1’Cer] 
Branching from Lac-Cer, GM3 is the defining molecule of the ganglio-series. 
GD3, the first molecule in the subsequent b-series pathway requires the addition of a 
sialic acid to the existing structure of GM3. It must be noted that neither GT3, nor the 
subsequent molecules in the c-series pathway have been shown to exist in the mouse. 
Like GM4, GM3 has immunosuppressive properties and is useful in probing which 
elements of ganglioside structure are critical to their biological activity (51). The 
lymphocyte homing receptor, L-selectin (LECAM-1) binds it at a lower affinity than its 
corresponding sulfatide (52). It has also been used to examine binding specificities of the 
sialoadhesin family of I-type lectins (32), and is not the carbohydrate ligand of E-selectin 
(53). It is weakly recognized by monoclonal antibody AM-3 which was raised against a 
sialomucin from human colorectal carcinoma (54), and one of the monoclonal antibodies 
raised against this ganglioside reacts selectively with helper memory T cells (55). GM3 
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inhibits lung metastases produced by intravenous co-injection of B16-BL-6 melanoma 
cells (56). And like the gangliosides discussed so far, GM3 also plays a role in mouse 
embryogenesis by appearing in all tissues during E9 and E11, various neural and non-
neural tissues by E13, and centering in the telencephalon, non-neural tissues and liver 
tissues by E15 (57). A parallel can be drawn in tumorigenesis by studying GM3’s 
appearance in MEB4 murine melanoma cells (58), GRX mouse hepatic stellate cells (59), 
the murine Lewis lung carcinoma cell line LL2, cultured tumor cells of the VM mouse 
strain (60), and the lungs of mouse B16 melanoma. It is also present in normal muscle 
tissue (30), the uterus (29), macrophages, and high metastatic (Eb) potential cells (33). 
Both NeuAc and NeuGc are present in the ICR mouse spleen (39) and the mouse liver, 
while only NeuGc remains in the murine adrenal gland (24).  
 
Monosialoganglioside GM2 [GalNAcβ1-4(NeuAcα2-3)Galβ1-4Glcβ1-1’Cer] 
Since GM2 is the next step in GM3 anabolism, it is present in most of the tissues 
that its precursor is in. These include cultured tumor cells of the VM mouse strain (60), 
GRX mouse hepatic stellate cells (59), the murine Lewis lung carcinoma cell line LL2, 
lungs of mouse B16 melanoma, high metastatic (Eb) potential cells (33) and 
macrophages. However, this molecule also appears in the erythrocytes of C3H/He and 
CDF1 inbred mouse strains (25). Only NeuGc has been shown to be in the mouse liver 
and the ICR mouse spleen (39). Impaired catabolism of GM2 causes Tay-Sachs disease. 
The disease can be caused by the resistance of the terminal GalNAc to β-hexosaminidase 
A (Hex A) in the absence of the protein cofactor GM2 activator protein (61) which is 
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required to assist in the hydrolysis of GM2 (62,63), or from a deficiency of Hex A (64-
66).  
 
Monosialoganglioside GM1a [Galβ1-3GalNAcβ1-4(NeuAcα2-3)Galβ1-4Glcβ1-1’Cer] 
GM1a has been shown to interact with the hormones FSH, LH and HCG, and 
bind to tetanus toxin (67,68), cholera toxin (69,70), and botulinum toxin (71). It appears 
in cultured tumor cells of the VM mouse strain (60), GRX mouse hepatic stellate cells 
(59), the murine Lewis lung carcinoma cell line LL2, and in myelogenous leukemias 
(27). Normal tissues containing this molecule include muscle (30), brain, the ICR mouse 
spleen (39) and other high metastatic (Eb) potential cells (33). Unlike GM2, it only 
appears in peritoneal macrophages and immature T cells. It is also enriched in myelin in 
sg/sg mice (72). GM1a containing NeuGc is present in the liver.  
 
Disialoganglioside GD1a [NeuAcα2-3Galβ1-3GalNAcβ1-4(NeuAcα2-3)Galβ1-4Glcβ1-
1’Cer] 
Like its precursor GM1, GD1a is present in cultured tumor cells of the VM mouse 
strain (60), GRX mouse hepatic stellate cells (59), the murine Lewis lung carcinoma cell 
line LL2, a differentiation-resistant clone of mouse myeloid leukemia cells, M1-R1 (45), 
and in normal tissues such as muscle (30), brain, murine macrophages and other high 
metastatic (Eb) potential cells (33). GD1a (NeuGc, NeuGc) is found in the mouse liver.  
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Trisialoganglioside GT1a [NeuAcα2-8NeuAcα2-3Galβ1-3GalNAcβ1-4(NeuAcα2-
3)Galβ1-4Glcβ1-1’Cer] 
GT1a is enriched in Purkinje cells, more concentrated in branchlet spines than in 
other regions of the Purkinje cell membrane in sg/sg mice (72). 
 15
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1.2.2.3 b-series 
Disialoganglioside GD3 [NeuAcα2-8NeuAcα2-3Galβ1-4Glcβ1-1’Cer] 
GD3 appears in murine microglia upon exposure to inflammatory stimuli. GD3 
and its acetylated form, 9-O-acetyl GD3 appear in the fetal cortex during development 
(73). It presents in reactive glia of sg/sg mice at very high levels, accumulates through 
adulthood (72). While no evidence exists to prove the presence of the subsequent GD2, it 
may be hypothesized that it is found in mouse tissue by functioning as an intermediate in 
the pathway from GD3 to GD1b. 
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Disialoganglioside GD1b [Galβ1-3GalNAcβ1-4(NeuAcα2-8NeuAcα2-3)Galβ1-4Glcβ1-
1’Cer] 
GD1b appears in mouse muscle (30), brain and other tissues that include cells 
with a high metastatic (Eb) potential cells (33). It has a fatty acid composition of 
d18:1/C18:0 (74), and is also found in the human brain (75). 
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Trisialoganglioside GT1b [NeuAcα2-3Galβ1-3GalNAcβ1-4(NeuAcα2-8NeuAcα2-
3)Galβ1-4Glcβ1-1’Cer] 
Similar to its precursor GD1b, GT1b (75) exists in mouse muscle (30) and brain 
tissues. Enriched in both granule cells and Purkinje cells in sg/sg mice (72). A variant of 
this molecule, GT1bα with the terminal sialic acid residue moved to GalNAc (NeuAcα2-
6 → GalNAc) is reactive with the anti-cholinergic neuron specific antibody (anti-Chol-1), 
and has a composition of the ceramides d20:1/C18:0 and d18:1/C18:0 (76).  
 
Tetrasialoganglioside GQ1b [NeuAc2-8NeuAcα2-3Galβ1-3GalNAcβ1-4(NeuAcα2-
8NeuAcα2-3)Galβ1-4Glcβ1-1’Cer] 
This molecule is mainly present in the mouse brain tissues. The alpha variant of 
GQ1b (d18:1/C18:0) where the terminal sialic acid has shifted to GalNAc (NeuAcα2-6 
→ GalNAc) is one of the most potent neuronal ligands for myelin-associated 
glycoprotein (77), and has been used to examine the binding specificities of the 
sialoadhesin family of I-type lectins (32).  
A novel structure, NeuAcα2-3Galβ1-3GalNAcβ1-4(Ac-O-9NeuAcα2-8NeuAcα2-
3)Galβ1-4Glcβ1-1’Cer is also present in the mouse brain (78). 
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1.2.3 Lacto-series [Galβ1-3GlcNAcβ1-3Galβ1-4Glcβ1-1’Cer] 
Type I H antigen (Fucα1-2Galβ1-3GlcNAcβ1-3Galβ1-4Glcβ1-1’Cer) 
The H blood group antigen is present in ectoblastic derivatives (ectodermal and 
neuroectodermal components) of murine teratocarcinoma. The presence of this antigen 
can be used to presume the existence of its precursors, Lc3Cer (GlcNAcβ1-3Galβ1-
4Glcβ1-1’Cer) and Lc4Cer (Galβ1-3GlcNAcβ1-3Galβ1-4Glcβ1-1’Cer) in the mouse.  
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Sialyl Lea [Galβ1-3GlcNAcβ1-3Galβ1-4Glcβ1-1’Cer] 
A product of NeuAcα2-3Galβ1-3GlcNAcβ1-3Galβ1-4Glcβ1-1’Cer which in turn 
was derived from Lc4Cer, sialyl Lea appears in undifferentiated embryonic cells in a pre-
implantation embryo from the 8-cell during E14 (79).  
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1.2.4 Neolacto-series [Galβ1-4GlcNAcβ1-3Galβ1-4Glcβ1-1’Cer] 
A root molecule containing a β-configuration of (1-4) instead of (1-3) in the 
terminal galactose converts lacto-series into neolacto-series. Molecules such as 
disialosyl-lacto-N-neotetraosylceramide (LD1) in this family can be found in purkinje 
cells and the mouse cerebellum (73). The O-acetylated form of LD1 is present in the fetal 
cortex during embryogenesis, and persists in the adult mouse cerebellum (73).  
 
Paragloboside [Galβ1-4GlcNAcβ1-3Galβ1-4Glcβ1-1’Cer] 
Lacto-N-neotetraosylceramide, or nLc4Cer can be found in the mouse cerebellum, 
the murine leukemia cell line M1, and in muscle tissue (30).  
 
 
Sialosylparagloboside [NeuAcα2-3Galβ1-4-GlcNAcβ1-3Galβ1-4Glc1-1’Cer] 
As its name implies, sialylparagloboside, or sialyl-neolactotetraosylceramide (80) 
consists of a sialic acid residue attached to the aforementioned nLc4Cer. It is present in 
mouse muscle+B187, and the molecule containing NeuGc appears in the ICR mouse 
spleen (39). 
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SSEA-1, Lex [Galβ 1-4(Fucα1-3)GlcNAcβ1-3Gal-β1-4Glcβ1-1’Cer] 
This stage-specific embryonic antigen-1 (SSEA-1) is expressed in murine EC 
cells, more specifically in the inner cell mass. It has been suggested that this molecule 
mediates the compaction of the mouse embryo (81). 
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Sialyl Lex [NeuAcα2-3Galβ 1-4(Fucα1-3)GlcNAcβ1-3Gal-β1-4Glcβ1-1’Cer] 
Sialyl Lex  is fucosylated sialosylparagloboside, and is recognized by three 
components of the selectin receptor family that participate in the initial interactions 
between leukocytes and vascular endothelia (82), although it is not the carbohydrate 
ligand of E-selectin (53). It appears during E14 in the pre-implantation mouse embryo 
from the 8-cell stage (79). The lymphocyte homing receptor, L-selectin (LECAM-1) 
binds it at a lower affinity than its corresponding sulfatide (52). It has also been used to 
examine binding specificities of the sialoadhesin family of I-type lectins (32). It is weakly 
recognized by monoclonal antibody AM-3 which was raised against a sialomucin from 
human colorectal carcinoma (54), and one of the monoclonal antibodies raised against 
this ganglioside reacts selectively with helper memory T cells (55). Sialyl Lex inhibits 
lung metastases produced by intravenous co-injection of B16-BL-6 melanoma cells (56).  
 
Type II H antigen [Fucα1-2Galβ1-4GlcNAcβ1-3Gal-β1-4Glcβ1-1’Cer] and Type III H 
antigen [Fucα1-2Galβ1-3GalNAcα1-3(Fucα1-2)Galβ1-4GlcNAcβ1-3Gal-β1-4Glcβ1-
1’Cer] 
Type II H antigen and Type III H antigen are found in the ectodermal and 
neuroectodermal parts of murine teratocarcinoma (25). The intermediates in the pathway 
from nLc4Cer to Type II H antigen (nLc5Cer and nLc6Cer) and from Type II H  antigen 
to Type III H antigen have not been found experimentally in the mouse, although can be 
presumed to exist in minor amounts.  
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1.2.5 Globo-series [Galα1-4Galβ1-4Glcβ1-1’Cer] 
These molecules are more prevalent in the mouse, and play a role in lung (28), 
muscle (30), kidney (83), uterus (29), and especially embryonic tissues. SSEAs involved 
with embryogenesis also belong in this family, and have been used to show that a shift of 
glycolipid synthesis from globo-series to lacto-series glycolipids might occur in pre-
implantation mouse embryos (34). These neutral molecules are also present in murine 
myelogenous leukemias (27).  
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Globotriaosylceramide Gb3Cer[Galα1-4Galβ1-4Glcβ1-1’Cer] 
The first molecule in the pathway for globo-series, Gb3Cer is in the murine 
adrenal gland (24), uterus (29) and myelogenous leukemias (27).  
 
Globotetraosylceramide Gb4Cer [GalNAcβ1-3Galα1-4Galβ1-4Glcβ1-1’Cer] 
Like its precursor Gb3Cer, Gb4Cer is present in the murine adrenal gland (24), 
uterus (29) and myelogenous leukemias (27). However, it moves to mouse muscle (30) 
and is also present in the murine Lewis lung carcinoma cell line LL2, F9 cells (84), 
WHT/Ht mouse thymoma and thymocytes (85) and in embryonic and extra-embryonic 
tissues (84). Minor amounts of it are present in NF-1 cells (84). 
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SSEA-3, Globopentaosylceramide Gb5Cer[Galβ1-3GalNAcβ1-3Galα1-4Galβ1-4Glcβ1-
1’Cer] 
SSEA-3, a stage-specific embryonic antigen is present in the visceral yolk sac and 
placenta (84). It has been detected on surfaces resembling the primitive endoderm and 
trophectoderm in murine teratocarcinoma-derived cell lines (84). Gb5Cer can also be 
located in the mouse adrenal gland (24) and kidney (83). 
 
SSEA-4 antigen [NeuAcα1-3Galβ1-3GalNAcβ1-3Galα1-4Galβ1-4Glcβ1-1’Cer] 
The molecule subsequent to SSEA-3, SSEA-4, or GL7 is also a stage-specific 
embryonic antigen, and commonly occurs in the visceral yolk sac and placenta in the 
developing mouse embryo (84). 
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Forssman antigen [GalNAcα1-3GalNAcβ1-3Galα1-4Galβ1-4Glcβ1-1’Cer] 
Forssman antigen is also present in embryonic and extra-embryonic tissues, 
specifically in the visceral yolk sac and placenta (84). It shows no Lewis activity in the 
mouse small intestine (86), although is present in muscle tissue (30), F9 cells (84), and 
murine myelogenous leukemias (27).  
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Globo-Lex-9 [Galβ1-4(Fucα1-3)GlcNAcβ1-6(Galβ1-3)GalNAcβ1-3Galα1-4Galβ1-
4Glcβ1-1’Cer] 
Globo-Lex-9 and its precursor [Galβ1-3(GlcNAcβ1-6)GalNAcβ1-3Galα1-
4Galβ1-4Glcβ1-1’Cer] appear in the mouse kidney (83). 
 
Type IV H antigen [Fucα1-2Galβ1-3GalNAcβ1-3Galα1-4Galβ1-4Glcβ1-1’Cer] 
Similar to the H blood group antigens in the neolacto-series, Type IV H antigen 
has also been detected on the ectodermal and neuroectodermal parts of murine 
teratocarcinoma (25).  
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1.2.6 Isoglobo series GSLs [Galα1-3Galβ1-4Glcβ1-1’Cer] 
The isoglobo series of GSLs are derived from a relatively minor GSL biosynthesis 
pathway catalyzed by iGb3 synthase (iGb3S) (87). 
 
Isoglobotrihexosylceramide, iGb3Cer [Galα1-3Galβ1-4Glcβ1-1’Cer] 
iGb3Cer was detected solely in the dorsal root ganglion in wild type mice (87) and 
is likely to be a natural invariant natural killer T cell-selecting ligand in the thymus of 
mouse (87). 
 
Isoglobotetrahexosylceramide, iGb4Cer [GalNAcβ1-3Galα1-3Galβ1-4Glcβ1-1’Cer] 
It has been reported that mouse kidney lacks iGb4Cer (88). 
 
 
 
1.2.7 Sulfated GSLs 
The sulfate group generally attaches to the terminal end of the growing 
monosaccharide chain at C3. Usually, these molecules are ligands for L-selectin, the 
lymphocyte homing receptor (52). In the mouse, both sulfated and bis-sulfated GSLs are 
abundant in the kidney. Such molecules include lactosylsulfatide [SM3, HSO3 -3Galα1-
 37
4Glcβ1-1’Cer], bis-sulfo-gangliotetraosylceramide [SB1a, HSO3 -3Galβ1-3GalNAcβ1-
4(HSO3)Galβ1-4Glcβ1-1’Cer] and gangliotriaosylceramide sulfate [SM2a, GalNAcβ1-
4(HSO3-3)Galβ1-4Glcβ1-1’Cer] (89,90). Sulfogangliotetraosylceramide [SM1b, HSO3-
3Galβ1-3GalNAcβ1-4Galβ1-4Glcβ1-1’Cer] stands as an exception and is present in the 
mouse intestine (91,92). 
 
Galactosylsulfatide [HSO3-3Galβ1-1’Cer]  
Galactosylceramide 3-sulfate (SM4s) plays a role in the stimulation of the 
evolution of oxygen radicals in polymorphonuclear leukocytes (93). Moreover, it 
interacts with the GM2 activator protein (94), and cannot be hydrolyzed by 
glucosulfatase (95). In addition to the murine kidney (90,96), it is present in myelin 
components (97,98), specifically the myelin sheath in the mouse brain. 
 
 
1.2.8 Gala-series [Galα1-4Galβ1-1’Cer] 
Only one molecule from this series, galabiosylceramide (Galα1-4Galβ1-1Cer) has 
been found in the kidney of BALB/c, A, and C57/BL mouse strains (99). It plays a role in 
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the modulation of the affinity of alpha-interferon for its membrane protein receptors in 
human cells (100). Its level fluctuates in the mouse on account of sex hormones (101). 
 
 
1.2.9 Sulfoglucuronyl-neolacto series  [HSO3-3GlcUβ1-3Galβ1-4GlcNAcβ1-3Galβ1-
4Glcβ1-1’Cer] and [HSO3-3GlcUβ1-3Galβ1-4GlcNAcβ1-3Galβ1-4GlcNAcβ1-
3Galβ1-4Glcβ1-1’Cer] 
This family of GSLs is unique in that it includes the monosaccharide glucuronic 
acid (GlcU) on the carbohydrate moiety of sulfated glycolipids in the neolacto-series. 
Also known as sulfoglucuronylglycolipids (SGGLs), or HNK-1 antibody glycolipids on 
account of detection via a reaction with HNK-1, these are primarily adhesion molecules 
of neurons (102), and are present in mouse purkinje cells (103), peripheral nerves 
(104,105), and the cerebellum (103,106). On comparing the fatty acid composition of all 
molecules of SMUnLc4Cer, 13% are C16:0, 16% are C18:1, 11% are C18:0, 13% are 
C24:1, and 15% are C24:0 (107). 
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1.2.10 Psychosine, galactosylsphingosine  
Globoid cell leukodystrophy or Krabbe disease is an antosomal recessive 
inherited neurological disorder caused by the deficiency of the lysosomal enzyme β-
galactobrosidase (108,109). The twitcher mouse is an authentic murine model of Krabbe 
disease (110,111) and shows a remarkable accumulation of psychosine in the brain, 
spinal cord and peripheral nerves (108,109,111-113). 
 
1.3. Roles in development 
A remarkable change of expression of carbohydrate markers has been reported in 
early embryo, embryonic stem (ES) and embryonic carcinoma (EC) cells (114). During 
mouse embryogenesis in vitro, the globo-series GSLs (SSEA-3 and SSEA-4) express 
highly at earlier stage (2-to-4-cell stage) of embryo. As SSEA-3 and SSES-4 decrease 
and disappear, the neolacto-series GSL (SSEA-1) first appears at late 8-cell stage and 
express highly at 16-to-32-cell stage. And another globo-series GSL, forssman antigen, 
begins to be expressed on late morulae in mouse development (115). SSEA-3 disappears 
faster than SSEA-4 (114). After differentiation, these antigens are down-regulated (116). 
SSEA-1 is greatly expressed in mouse EC cells, but disappears after most cells are 
differentiated completely in vitro (117).  These data suggest that glycolipid core 
structural changes regulated by a few key glycosyl transferases may be critical during cell 
differentiation in embryogenesis and during oncogenesis (114). 
Although the expression of SSEAs is strictly controlled during embryogenesis, 
SSEA-1 has been suggested that mediate compaction, a tight adhesion of the blastomeres, 
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in mouse embryos, and a function of SSEA-3 and SSEA-4 may be related to the P-blood-
group system (114,116,118,119).  
GSLs have also important roles in mouse brain developments.  Gangliosides (GM2, 
GM1, GD3, GD1a, GD2, GD1b, GT1b, GQ1b, GT3, GQ1c, GT1aα and GQ1bα) and 
different categories of GSLs (Glc-Cer, Gal-Cer, Sulfatide and Lex) have developmental 
changes of their expression patterns in developing mouse brains. GD3 is the most 
abundant expressed ganglioside at E12 to E14 (120). As GD3 and GM3 decrease, GD1a 
increases after E16 (120). Glc-Cer, SSEA-1 and GT3 are also expressed in embryonic 
mouse brains (120). Therefore, SSEAs may be useful to identify, isolate, or specifically 
target EC cells (121,122) and the dramatic changes in GSL pattern and content can serve 
as important markers in developmental biology. 
Day 0 0.5 1 1.5 2 2.5 3.5 7 
SSEA-1 (Lex) - - - ++ +++ + + - 
(Ley) - - - - - - ++ - 
SSEA-3/4  ++ +++ + + - -  
Gb4   + ++ +++ - ?  
Ganglio-Series  - - - - - - +/++ 
              
Figure 1.2. Glycosphingolipidomic role in defining tumor potency (Hakomori 2002). 
SSEA-1 (Lex) is not expressed until morula stage, declines after compaction, and is 
restricted to inner cell mass of blastocyst. SSEA-3 and -4 are expressed highly at four-
cell stage and decline later. Globoside (Gb4) is expressed maximally at morula stage. 
Ganglio-series epitopes are not expressed during the preimplantation stage, but appear 
only upon further differentiation (neural crest formation).  
 
 41
Table 1.2. Functions of GSLs in tumors (Hakomori 2000) 
Tumor associated 
GSLs 
Binding to E-selecting on activated EC 
Platelet activation to release factors that activate EC 
Gal- or sialic acid-binding lectins expressed on target cells 
Promotion or inhibition of angiogenesis 
Multiple drug resistance associated with ceramide: 
glycosylation 
Binding to carbohydrates expressed on EC (carbohydrate-
carbohydrate interaction) 
 
 
1.4. Roles in tumorigenesis 
Little is known about the mechanisms through which specific GSLs induce invasive 
and metastatic phenotypes of tumor cells. However, high expression of some GSLs 
promotes invasion and metastasis of tumor cells. Sialyl-Lex, sialyl-Lea, Ley, GM2, GD3, 
and sialyl-Gb5 promote invasion and metastasis of cancer (123). On the other hand, 
expression of some other GSLs suppresses tumor progression, for examples, 4GlcNAc 
competitive with 6GlcNAc; histo-blood group A and B competitive with sialylated 
structures including sialyl-Lex and sialyl-Lea; Gb5 competitive with sialyl-Gb5 (61,123).  
Lac-Cer was claimed to inhibit apoptosis, mainly through increased Bcl-2 and 
decreased caspase expression (123,124). Apoptosis was previously found to be associated 
with Ley expressed in various types of cancer (125) and continuous expression of GM3 in 
Chinese hamster ovary mutant ldlD, associated with CD9 and CD82, induces apoptosis, 
because GM3 inhibits cell motility and invasiveness when complexed with CD9 or CD82 
(126). However, a different ganglioside monosialo-Gb5, complexed with CD9 in breast 
cancer MCF7 cells, strongly enhances motility and invasiveness (127). Similar 
considerations may apply to the inhibitory effect of GM3 on epidermal growth factor 
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(EGF) receptor tyrosine kinase (128). GM3 in mouse ependymoblastoma tumor cell line 
EPEN inhibits tumor growth and angiogenesis, whereas induction of GM2, GM1, and 
GD1a synthesis through β4GalNAc-T transfection leads to higher vascularization and 
enhanced endothelial growth factor (VEGF) production (129). GD3 may promote tumor 
cell motility and growth, possibly through angiogenesis and vascular VEGF production, 
as evidenced by antisense approach using GD3 synthase gene (130). 
SLex and SLea have been identified as tumor-associated antigens and as E-selectin 
epitopes, and may promote adhesion of tumor cells to endothelial cells. Clinically, 
expression of SLex (131) and SLea (132) is inversely correlated with postoperative 
survival rate of patients. Therefore, GSLs involved in tumor cell metastasis are targets for 
cancer therapy, such as antitumor vaccines. 
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Tumor
GM3
LacCer
Bcl2 ↑
Caspase ↓
Apoptosis ↓
GD3 VEGF ↑ Angiogenesis ↑
A3/CD9/GM3 
complex
Motility ↓ EGFR ↓
Tyrosine 
Kinase
Gb3 Gb5 DSGb5 Siglec
MSGb5/CD9 Motility ↑
β6GlcNAc 
branch
Angiogenesis ↑
Matriptase ↑
β6GlcNAc 
(bisecting GlcNAc)
Tn
“core 2”
SLea, SLex Sialyl-6-sulfo-Lex
E-selectin P-, L-selectins
STnSiglec
Lc3
Lc4
nLc4
SLea
SLex
E-selectin
Cadherin ↓
1 2 3
4
9
5
8
88
9
77a
6b
6
6a
 
Figure 1.3. Glycosphingolipidomic role in defining tumor potency (Hakomori 2002). 
Tumor cell malignancy is defined by several key phenotypes: apoptosis (route 1), 
motility (routes 2 and 5), EGF receptor tyrosine kinase (route 3), angiogenesis (routes 4 
and 6b), matriptase (matrix-destroying enzyme) activity (route 6a), self-adhesion 
(through cadherin) (route 7a), adhesion to ECM (through integrin), adhesion to ECs and 
platelets (through E- or P- selectin) (route 8), adhesion to blood cells and other 
parenchymatous cells (through siglecs) (route 9). Each phenotype is up- or down- 
regulated (↑, ↓) by different status of glycosylation as indicated in the figure. 
Phenotypes with (↑, ↓) and routes 2, 3, and 7a,   and   inhibit tumor invasiveness. Those 
with (↑, ↓) and routes 1, 4, 5, 6a, 6b, and 8 promote tumor invasiveness. Glycosyl 
epitopes capable of binding to specific ligands promote invasiveness. Some ligands 
(α3/CD9/GM3 complex, tyrosine kinase and siglec) have variable or unclear effect on 
invasiveness. A given phenotype is produced by different glycosylations, and a given 
glycosylation produces different phenotypes. Phenotypic changes have cooperative 
effects on malignancy. For instance, GM3 inhibits motility through α3/CD9 complex, and 
also inhibits EGF receptor tyrosine kinase (routes 2 and 3). Reduction of GM3 inhibits 
apoptosis (route 1), but also promotes motility and proliferation (negative route 2 and 3 
effect). All glycosylation pathways catalyzed by multiple glycosyltransferases and their 
genes are well established, although the mechanism by which each type of glycosylation 
affects the various phenotypes remains to be studied. 
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1.5 Mouse models 
The deficiency of degradation of GSLs may cause serious physiological problems 
because of the importance of the balance between synthesis and degradation. Gal-Cer 
synthase (ceramide galactosyltransferase, CGT) knockout mice generate severe 
generalized tremor, mild ataxia and conduction deficits and male sterility (133). The 
severe dysmyelinosis leads to the death of the null mice at the end of the myelination 
period, because Gal-Cer and/or sulfatides play important roles in myelin function and its 
stability (133). The knockout mice of sulfatides synthase lead to similar neurological 
abnormalities and disrupt spermatogenesis to Gla-Cer knockout mice (134).  
The knockout mice of Glc-Cer synthase (GST) resulted in a complete loss of GlcCer 
and die at 7.5 embryonic day (135). This suggests that GSL synthesis is important for 
embryogenesis. Although embryogenesis proceeded into the primitive germ layers in 
case of the Ugcg- / - embryos, the overall embryonic structure was halted by a massive 
apoptotic process (134).  
The GD3 synthase knockout mice resulted in the increase of all a-series gangliosides 
and the loss of all b-series gangliosides (136,137). Although there is no remarkable 
morphological changes in these null mice, the regenerative activity were reduced in the 
hypoglossal nerve resection system (137). The mice lacking GM2/GD2 synthase showed 
complete loss of gangliosides such as GM1, GD1a, GD1b, GT1b, GQ1b, GM2, GD2, and 
asialo-series gangliosides (138). The GM2/GD2 synthase null mice induced a mild 
damage of nerve system (138) and a severe disruption of male fertility (139). Double 
knockout mice of the GD3 synthase and GM2/GD2 synthase had only GM3 ganglioside 
and were born and grew up almost normally at a glance (140). However, they started to 
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die suddenly at 12 weeks after birth or later by unknown reason and had refractory skin 
lesions (140). There is another report that this genetic disruption caused an audiogenic 
seizure and consequent sudden death by noise (137).  
These knockout studies in mice have shown that GSLs are critical in development 
and differentiation. 
 
1.6 Future directions 
Knowledge about existing GSLs in murine tissues is in tandem with the development 
and discoveries regarding new structures are constantly underway. These molecules are 
structurally very diverse, and uncovering each nuance of the glycan and lipid structure 
will require analysis via methods such as mass spectrometry and an understanding of 
their metabolic pathways in murine tissues. On the other hand, knowing the functional 
role of GSLs in signal transduction, membrane leaflets, embryogenesis and tumorigenesis 
will also help predict structures.  
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CHAPTER 2 
TRANSCRIPT PROFILING AND METABOLOMIC ANALYSIS OF 
CERAMIDE BIOSYNTHESIS IN MOUSE EMBRYONIC STEM 
CELLS AND EMBRYOID BODIES 
2.1 Introduction 
 Sphingolipids (SL), including glycosphingolipids (GSL), are ubiquitous 
components of all eukaryotic organisms (1) and participate in cell-type specific 
recognition, cell-cell interaction, cell-substratum adhesion, cell signaling and other events 
in embryogenesis (2-4). The lipid backbones of SL are sphingoid bases and N- acyl 
sphingoid bases (termed ceramides, Cer), which are known to change in amount during 
embryogenesis (2-6) and to be important in developmental signaling (4, 7-10). 
 Ceramides are biosynthesized by de novo (1, 11) and recycling (12) pathways that 
have been well characterized with respect to the genes for most of the early steps of the 
pathway (i.e., production of ceramide, Cer, and its initial metabolites) (1, 11, 13, 14). As 
depicted in Figure 2.1A,1 a modified KEGG pathway (Kyoto Encyclopedia of Genes and 
Genomes, http://www.genome.ad.jp/kegg/pathway/ map/map00600.html) (15), the de 
novo biosynthetic pathway starts with condensation of serine and palmitoyl-CoA by 
serine palmitoyltransferase (SPT) (16) to form 3-ketosphinganine (3-Keto-Sa) which is 
reduced to sphinganine (Sa) then acylated to dihydroceramides (DHCer) by a family of 
                                                 
 
 
1 Fig. 2.1 displays only mammalian genes and includes genes that have not yet been 
added to the online KEGG pathway for sphingolipids; for more information, see 
www.sphingomap.org. 
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ceramide synthases, CerS, that differ in fatty acyl-CoA selectivity as shown in Fig. 2.1B 
(17-20). DHCer can be incorporated into more complex SL, as shown in the lower left 
corner of Fig. 2.1A, or converted to Cer by addition of a 4-trans-double bond to the 
sphingoid base backbone (21), then incorporated into more complex SL (in some tissues, 
the lipid backbones are also hydroxylated on the sphingoid base (22) and/or fatty acid 
(23)). 
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Figure 2.1 Depiction of the early steps of sphingolipid biosynthesis using a modified 
KEGG pathway scheme (Sphingo-GenMAPP) to facilitate visualization of differences in 
gene expression in by R1 mESCs and EBs.  (A) Sphingolipid de novo biosynthesis (B)  
Expansion of the pathway to depict the individual molecular species made by different 
CerS isoforms (formerly named Lass), with abbreviation of the sphingoid base as d18:0 
for sphinganine (citing the number of hydroxyl groups, d for dihydroxyl), d18:1 for 
sphingosine, and the N-acyl chain length and number of double bonds as Cx:y, 
respectively.  As described in the text, the “heat” scale depicts the relative amounts of 
mRNA for each of these genes for R1 EBs versus mESCs as measured by qRT-PCR. 
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 None of the previous studies of sphingolipids in embryogenesis have explored 
whether there are developmental changes in the backbone Cer subspecies. Therefore, this 
investigation has analyzed expression of the CerS genes (17, 19, 24) and the amounts and 
types of Cer subspecies in mouse ESCs (mESCs) compared to embryoid bodies (EBs) as 
part of an investigation of all of the known genes for sphingolipid biosynthesis (25). Also 
analyzed were the co-substrate fatty acyl-CoAs and expression of the mRNA for fatty 
acid elongases and desaturases. These studies found that there were shifts in the 
expression of many of the genes of this pathway as well as in the associated metabolites 
in EBs versus ESCs. 
2.2 Experimental Procedures 
2.2.1 Growth and Characterization of mESCs and EBs 
 The R1 and D3 mESCs (26,27) (ATCC, Manassas, VA) were cultured in the 
absence of feeder cells on tissue-culture-grade plastic ware pre-coated with 0.1% gelatin-
phosphate buffered saline (PBS), as described previously (28). The mESC culture 
medium consisted of Dulbecco’s Modified Eagle Medium (DMEM, Gibco BRL) 
supplemented with 10% fetal calf serum (GIBCO BRL), 1 mM L-glutamine, 0.1 mM 2-
mercaptoethanol, 100 U/ml penicillin, 100 U/ml streptomycin and 1000 U/ml 
recombinant human LIF (Leukemia inhibitory factor; ESGRO, Chemicon International) 
at 37°C under 10 % CO2. 
 Differentiation of mESCs into EBs was carried out as described previously (29). 
mESCs were harvested by trypsinization to convert suspensions of single ESCs into 
aggregates that were seeded into 10-cm bacteriological dishes at a density of 1 × 105 
cells/ml, in 10 ml mESC-medium lacking LIF. EBs were harvested daily, the medium 
was changed every 2 days and cultures were split one into two at day 4. Cell populations 
of mESCs and EBs were characterized by flow cytometry using the lineage specific 
marker CD9 and by transcript analysis using qRT-PCR.  
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2.2.2 Measurement of Gene Expression Levels Using quantitative RT-PCR (qRT-PCR) 
Primer Design and Validation  
Primer pairs for sphingolipid synthesis genes and control genes were designed 
within a single exon using conditions described in Nairn et al (25). Primer sequences and 
accession numbers for genes in this study are presented in Nairn et al. (30). Individual 
qRT-PCR reactions were also checked for efficiency 100 ± 5% using reaction raw 
fluorescence data in the LinReg PCR program (31). 
 
Total RNA Isolation and cDNA Synthesis  
mESCs and EBs (day 6) cell pellets were harvested and flash frozen in liquid 
nitrogen and stored at -80ºC until use.  Cell pellets were homogenized followed by RNA 
isolation and cDNA synthesis which was performed as previously described (30). 
 
qRT-PCR reactions and Calculation of Relative Gene Expression Levels   
Triplicate reactions (20 μl each) containing 5 μl of diluted cDNA or genomic 
DNA template (primer validation reactions), 5 μl of primer pair mix (125 μM final 
concentration) and 10 μl of iQ™ SYBR Green Supermix (BioRad, Hercules, CA) were 
assembled in 96-well microtitre plates.  Amplification reactions and the calculation of 
relative gene expression levels was carried out as previously described (30). The control 
gene, Ribosomal Protein L4 (RPL4, NM_024212) was included on each plate to control 
for run variation and to normalize individual gene expression. 
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2.2.3 Integration of Gene Expression Data with Sphingo-GenMAPP pathway 
GenMAPP (Gene MicroArray Pathway Profiler; http://www.genmapp.org/) v2.1 
(32) is a tool to visualize global gene-expression profiles in the context of cell signaling 
pathways or KEGG metabolic pathways (http://www.genome.jp/kegg/).  In the context of 
the present study, the mRNA expression data for R1 mESCs and EBs from the qRT-PCR 
analysis was imported into a GenMAPP pathway for sphingolipid metabolism that had 
been modified (33) based on the current literature (34) (Fig. 2.1).   
 
2.2.4 Liquid Chromatography Electrospray Ionization Tandem Mass Spectrometry 
(LC ESI-MS/MS) 
Sphingolipids 
The SL were extracted from cells using published methods (35-37). Briefly, 
approximate 1 to 10 x 106 cells were scraped from culture dishes in a small volume of 
PBS, then centrifuged to remove excess PBS for a final volume of 0.05-0.1 ml.  The cells 
were suspended in 0.5 ml of CH3OH and 0.25 ml of CHCl3, spiked with internal 
standards for each species being monitored (see details below), disrupted using a bath-
type sonicator at room temperature, and incubated overnight in a heating block at 48°C.  
After cooling the tubes to room temperature, 75 μl of 1 M KOH in CH3OH was added 
and the mixture was sonicated for 30 sec, then incubated for 2 hr at 37°C.  The solution 
was neutralized with several μl of glacial acetic acid, 1 ml of CHCl3 was added followed 
by 2 ml of H2O, and sonicated.  After centrifugation, the upper phase was carefully 
removed and discarded.  The lower phase was dried using a SpeedVac and redissolved in 
0.3 ml of 98% of 97:2:1 CH3CN/CH3OH/CH3COOH (v/v/v) (mobile-phase A) and 2% of 
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64:15:20 CH3OH/H2O/CH3(CH2)3OH/CH3COOH (v/v/v/v) (mobile-phase B); both 
contained 5 mM ammonium acetate. 
The methods used for LC ESI-MS/MS analysis of sphingolipid metabolites have 
been reported in detail (36,37). SL data was collected using a Perkin Elmer Series 200 
MicroPump system (Perkin-Elmer, Norwalk, CT) coupled to a PE Sciex API 3000 triple 
quadrupole mass spectrometer equipped with a turbo ion-spray source (Applied 
Biosystems, Foster City, CA).  Complex SLs, such as Cer, CMH (ceramide monohexoses, 
the sum of glucosylceramide and galactosylceramide), and SM are separated by normal-
phase LC using 2.1 mm x 5 cm Supelco NH2 column (Supelco, Bellefonte, PA) at a flow 
rate of 1.5 ml/min.  The elution protocol was: 0.5 min of pre-equilibration of the column 
with 98:2 A/B (v/v), sample injection, elution with 98:2 A/B (v/v) for 1.1 min followed 
by a linear gradient to 82:18 A/B (v/v) in 0.2 min, elution at this composition for 0.4 min, 
then a linear gradient to 100% B over 0.8 min.  Afterwards, the column was 
reequilibrated by a 0.5-min linear gradient to 98:2 A/B (v/v) and a wash of the column 
with 98:2 A/B (v/v) for 0.3 min.  
Quantitation was performed by comparison of the unknowns with the spiked 
internal standards (IS), which were uncommon chain length homologs of each SL class: 
C12-ceramide, C12-sphingomyelin, and C12-glucosylceramide (for CMH), all of which 
were obtained from Avanti Polar Lipids (Alabaster, AL).  The IS were added as 10 µl of 
a 50 µM of stock for a total of 500 pmol of each IS molecular species per sample (see 
above).  Student’s t-test was used for statistical analyses. 
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Fatty Acyl-CoAs  
The fatty acyl-CoAs were extracted from cells using published method (38). The 
medium from cells cultured in 100-mm dishes was aspirated, and cells were gently 
washed twice with 5 ml of 4°C PBS, ~1 ml of ice-cold PBS was added, and the cells were 
scraped from the dishes using a rubber policeman and transferred to chilled 13 x 100 mm 
screw-cap borosilicate tubes with Teflon-lined caps (Kimble Chase, Vineland, NJ).  An 
additional ~1 ml of PBS was used to recover the remaining cells by this same procedure, 
and these were added to the first.   After centrifugation (1500 rpm, 3 min), the PBS was 
removed by aspiration and 0.5 ml of CH3OH containing 1 mM EDTA was added together 
with 10 μl of an IS mixture that contained 100 pmol each of C17:0- and C25:0-CoA, 
which were prepared in CH3OH/CHCl3 (2:1 v/v) containing 30 mM triethylammonium 
acetate.  After sonication (3 times at ~0.5 min each), 0.25 ml of CHCl3 was added, 
followed by another brief sonication. 
The single-phase extraction mixture was incubated in a 50°C heating block for 30 
min. After cooling to room temperature, CHCl3 and water (0.25 ml each) were added 
with mixing by vortexing after each addition.  After brief centrifugation using a table-top 
centrifuge, the fatty acyl-CoAs were in the upper phase and interface and most of the 
other lipids (which would interfere with the subsequent reverse-phase LC) were in the 
lower phase.  The upper phase was removed with a Pasteur pipette and transferred into a 
clean screw-cap glass tube. The upper layer was adjusted with 5% CH3OH (v/v), 5% 
butanol (v/v), and 5% CHCl3 (v/v).  These organic additives improved the stability of the 
very-long-chain acyl-CoAs for at least 24 hr at room temperature in the autosampler.  
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HPLC separations used a Shimadzu SCL-10A VP system controller, two LC-
10AD VP pumps, a DGU-14A degassing unit, a Perkin-Elmer series 200 autosampler, a 
Phenomenex (Torrance, CA) Gemini C18 column (2 mm ID x 150 mm with 3 μm 
particles, 110 Angstrom pores) and a 2 x 4 mm guard column with the same packing 
material.  A Metatherm column oven (Torrance, CA) was used to maintain the column 
temperature at 40°C. 
The flow rate was 0.2 ml/min in binary gradient mode with the following elution 
program: the column was equilibrated with mobile phase C [H2O/ CH3CN (85:15, v/v), 
containing 0.05% triethylamine], the sample was injected, and mobile phase C was 
continued for 5 min, followed by a 13 min gradient to 48% mobile phase C and 52% 
mobile phase D (CH3CN containing 0.05% triethylamine) during which the long-chain 
and very-long-chain fatty acyl-CoAs eluted.  Afterward, the column was washed by a 1- 
min gradient to 100% D and a 5 min hold at 100% D, followed by reequilibration of the 
column by a 1 min gradient to 100% C and a 5 min hold at 100% C before injection of 
the next sample. 
 Tandem mass spectrometry of fatty acyl-CoAs in positive ion mode was 
performed on a 4000 QTrap triple quadrupole linear ion trap mass spectrometer (Applied 
Biosystems, Foster City, CA) as recently described (38). 
 
2.3 Results 
2.3.1 Characterization of R1 mESCs and EBs 
 The R1 mESCs and EBs were examined for gross morphological changes and 
transcript abundances as markers for these cells.  The mESC’s expressed Zinc finger 
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protein 42 (zfp42/Rex1), Gastrulation brain homeobox (GBX2), and Nanog homeobox 
(Nanog) as pluripotent markers, and the qRT-PCR transcript profiles for Goosecoid (Gsc), 
Zinc finger protein of the celebellum 1 (Zic1), SRY-box containing gene 17 (Sox17), 
Alpha fetoprotein (Afp) and GATA binding protein 6 (Gata6) were typical for the 
transition from mESCs to EBs (25).  
 
2.3.2 Differences in the expression of sphingolipid metabolism genes in R1 mESCs 
and EBs using Sphingo-GenMAPP  
 The relative transcript expression levels of R1 EBs versus mESCs are depicted in 
the pathway diagram (Fig. 2.1) and with the fold differences shown by the “heat” scale 
defined on the right side of the figure.  There were no differences in the transcript levels 
for serine palmitoyltransferases (SPT1 and SPT2), the first enzymes of the pathway, but 
EBs had higher expression of transcripts for 3-ketosphinganine reductase and some of the 
CerS isoenzymes (CerS1, 3 and 6), as is also shown by bar graphs in Fig. 2.2 (upper 
panel).  The transcripts were also higher in EBs for enzymes that utilize Cer for 
biosynthesis of more complex sphingolipids, i.e., both of the SM synthases and the 
glycosyltransferases that produce GlcCer and GalCer (Fig. 2.1).  EBs had lower transcript 
abundances for the major desaturase that synthesizes Cer from DHCer (dihydroCer 
desaturase, DES1) and transcripts for the other desaturase (DES2, which makes 
phytoceramides) (22) were barely detectable in both mESCs and EBs. 
Since the CerS enzymes utilize very-long-chain fatty acyl-CoA’s that are made by 
elongation of palmitoyl- and stearoyl-CoA’s, the transcripts for the pertinent fatty acyl-
CoA elongases were also analyzed by qRT-PCR.  As shown in Fig. 2.1 and 2.2B, the 
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transcript level for Elovl6, a fatty acyl-CoA elongase that catalyzes the elongation of 
saturated and monosaturated acyl-CoAs with 12-16 carbons (39,40), was 4-fold higher 
for EBs than mESCs.  A fatty acyl-CoA elongase that extends C16:0-CoA to C24:0-CoA, 
Elovl3 (39,41,42) showed 3-fold higher transcript levels for EBs than mESCs, although 
lower transcript levels were observed for Elovl1, which is also responsible for elongating 
very-long-chain saturated fatty acyl-CoAs (39,43). EBs also had ~3.5-fold higher Elovl2 
(39,44) transcript levels, no evident change in Elovl4 (39,45) transcripts, and slightly 
higher Elovl5(39,44) transcript abundance (which are all elongases for polyunsaturated 
fatty acids). 
These differences in gene expression imply that the sphingolipid backbones of 
EBs might differ from mESCs by having:  i) higher proportions of subspecies with longer 
acyl chains (i.e., >C16) since EBs have a higher transcript abundance of CerS1, which is 
relatively specific for stearoyl-CoA (C18:0) (46), and CerS3, which is selective for very-
long-chain fatty acyl-CoA’s (>C20) (47); ii) higher, lower or unchanged C16-Cer since 
an elevation in CerS6(18), one of the CerS responsible for biosynthesis of C16-Cer, may 
be offset by a decrease in the transcripts encoding a CerS that utilizes C16-fatty acyl-CoA, 
CerS5(48); iii) increases in DHSL since DES1 is lower and DES2 unchanged; and iv) 
possibly lower amounts of (DH)Cer because the transcripts encoding most of the 
enzymes that metabolize (DH)Cer were elevated (including the transcripts for one of the 
ceramidases, Asah2).  The gene expression data also suggest that the EBs have the 
capacity to elongate fatty acyl-CoA’s to produce the co-substrates that are utilized to 
make these Cer subspecies.  To test these hypotheses, the Cer subspecies (and fatty acyl-
CoA’s) were analyzed by LC ESI-MS/MS. 
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Figure 2.2. Relative transcript abundance of CerS (Lass) genes (A) and fatty acyl-CoA 
elongase (Elovl) genes (B) by qRT-PCR for R1 mouse embryonic stem cells and day 6 
EBs.   
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2.3.3 Characterization of the Cer backbone subspecies of R1 mESCs and EBs 
 Fig. 2.3A shows the relative proportions of the Cer subspecies in R1 mESCs (day 
0) and EBs on days 4 and 6 as “donut” charts2.  The rationale for the latter depiction is 
that CerS’s have approximately the same Km for the sphingoid base substrate (49), 
therefore, as a first approximation, one would predict that the relative amounts of the 
different subspecies would correlate with the relative abundances of the respective CerS 
transcripts, which have been re-graphed in Fig. 2.3B to show the differences between 
mESCs and EBs.  The order of the CerS genes has been arranged so they correspond to 
the respective types of Cer that are made, i.e., C16-Cer (CerS6 and CerS5), C18-Cer 
(CerS1), C20 + 2 Cer (CerS4), C24-Cer (CerS2), and C26-Cer (CerS3) (c.f. Fig. 2.1).   
Comparison of Fig. 2.3A and B reveals a close correspondence between the 
differences in transcript abundances for CerS in mESC versus EBs and the Cer 
subspecies distribution:  a lower CerS6 + CerS5 for EBs vs mESC corresponding to a 
decrease in C16-Cer; higher CerS1 in EBs corresponding to an increase in C18-Cer; and 
higher CerS2 corresponding to a small increase in C24-Cer.  Lower CerS4 transcripts in 
EBs did not translate into a decrease in the sum of C18 + C20 + C22-Cer, however, this 
might be due to the large increase in CerS1 transcripts.   
                                                 
 
 
2 Bar graphs with the amounts of each subspecies of (DH)Cer, (DH)CMH and (DH)SM 
for R1 and D3 mESCs and EBs are available as Fig. 2.6 and 2.7. 
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Figure 2.3. Ceramide and fatty acyl-CoA composition of R1 mouse embryonic stem cells 
at different timepoints during EB formation.  (A) Cer subspecies distribution with the 
chain length and number of double bonds depicted by x:y, respectively, for mESCs and 
EBs after days 4 and 6.  The Cer subspecies were analyzed by LC ESI-MS/MS as 
described in references 35-37.  (B) Representation of relative changes in CerS transcript 
abundance of mESCs versus day 6 EBs arranged with the approximate order of the fatty 
acyl-CoA selectivities of the CerS to match the acyl-chain lengths of the Cer in panel A.  
(C) Fatty acyl-CoA subspecies of mESCs and EBs for days 2, 4, and 6.  
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2.3.4 Analysis of the fatty acyl-CoA species in R1 mESCs and EBs  
 The amounts of the fatty acyl-CoAs in R1 mESCs and EBs are shown in Fig. 
2.3C. During the time course for conversion of mESCs to EBs, C18:0- and C18:1-fatty 
acyl-CoAs increased by ca 2 fold, as did many of the very-long-chain (C22:0-, C24:0- 
and C24:1-) fatty acyl-CoAs. In contrast, palmitoyl-CoA derivatives (C16:0-) were 
approximately the same in mESCs and EBs.  Thus, these results are consistent with the 
observed changes in the higher amounts of C18:1-, C22:0-, C24:0-, and C24:1-fatty acyl-
CoAs in EBs versus mESCs.  These results additionally indicate that the CerS that would 
utilize these fatty acyl-CoAs to produce the pertinent Cer subspecies are not hampered by 
a lack of co-substrate availability during EB development. 
 
2.3.5 Characterization of the DHCer and Cer backbone subspecies of (DH)SL in R1 
mESCs and EBs 
The DHCer of mESCs and day 6 EBs also exhibited shifts in fatty acyl-chain 
length (Fig. 2.4A) that correlated with the differences in CerS expression that were 
similar to the changes in Cer (c.f., Fig. 2.4A and Fig. 2.4D), namely lower proportions of 
C16-DHCer and more C18-and C24/24:1 DHCer, which the greatest increase in C24:1-
Cer.  Since DHCer is the first N-acylated intermediate of de novo sphingolipid 
biosynthesis (Fig. 2.1) versus Cer, which is formed next and during the turnover of more 
complex sphingolipids, perhaps this accounts for the closer resemblance between the 
chain length subspecies of DHCer and the mRNA abundance of the CerS isoforms (c.f., 
Fig. 2.3A and 2.4).   
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 The (DH)CMH (Fig. 2.4B and E) and SM (Fig. 2.4F) of EBs displayed higher 
proportions of the C24/C24:1 backbones, however, most of the other subspecies 
differences that were seen in Cer and DHCer were not evident in these downstream 
metabolites.  
 There were also differences in the proportion of DHCer versus Cer backbones in 
EBs versus mESCs (which are not evident in Fig. 2.3 or 2.4 since the data are shown only 
as proportions within each category).  When summed across all chain lengths and 
categories, the total amount of these sphingolipids did not differ between mESCs and day 
6 EBs (i.e., 780 vs 740 pmol/mg protein, respectively), but the DHSL percentage 
increased from approximately 8% for mESCs to 19% for EBs.  This finding was 
consistent with the lower DES1 expression in EBs versus mESCs (Fig. 2.1). 
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Figure 2.4. Subspecies distributions of (dihydro)ceramides, (dihydro)ceramide 
monohexoses and (dihydro)sphingomyelins of R1 mouse embryonic stem cells and day 6 
embryoid bodies.   
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2.3.6 Characterization of the DHCer and Cer backbone subspecies of (DH)SL in D3 
mESCs and EBs 
To determine if these compositional changes were unique to the R1 cells, the 
lipids of another frequently studied mESCs, D3 cells (28), were analyzed by LC ESI-
MS/MS.  The two similarities were decreases in the proportion of C16-(DH)Cer and 
increases in C24/C24:1 (DH)Cer in D3 EBs versus mESCs, Fig. 2.5A and D).  
Furthermore, these differences were also more prevalent in the downstream metabolites 
(Fig. 2.5B, C, E and F).  Based on these similarities, it is possible that the phenomena that 
these shifts in (DH)Cer subspecies are common in this developmental transition. 
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Figure 2.5. Subspecies distributions of (dihydro)ceramides, (dihydro)ceramide 
monohexoses and (dihydro)sphingomyelins of D3 mouse embryonic stem cells and day 6 
embryoid bodies.   
 71
2.4 Discussion 
The goal of these studies was to explore whether mESCs undergo changes in 
expression of genes for the early steps of de novo sphingolipid biosynthesis upon 
conversion to EBs.  There were changes in transcript levels for many of the early 
enzymes of sphingolipid biosynthesis (Fig. 2.1), including increases in some of the CerS 
subspecies and downstream synthases for sphingomyelins and glycosphingolipids and 
decreases in some of the CerS, sphingosine kinases, and some of the ceramidases.  While 
all of these are worthy of further investigation, this study focused on analysis of 
(dihydro)ceramide backbones of mESCs and EBs using LC ESI-MS/MS to determine 
how well the changes in gene expression predicted changes in these important 
compounds.   
For all of the mESCs and EBs sphingolipids investigated in this study, the 
prevalent fatty acid of the (DH)Cer backbone was C16:0 (palmitate), which is 
biosynthesized by CerS5 and CerS6.  Consistent with this, the transcript abundance of 
CerS5 plus CerS6 is higher than that for most of the other CerSs (1, 3 and 4) except 
CerS2 (Fig. 2.2).  We do not know if CerS2 enzymatic activity is also relatively high 
(since transcript abundance is not necessarily equivalent to protein amount or enzymatic 
activity), but even if it is, the low amounts of the corresponding C24-fatty acyl-CoA’s 
might be rate limiting (Fig. 2.3C).  Consistent with this point of view, EBs had lower 
percentages of C16-(DH)Cer and higher (DH)Cer with C18- and very-long-chain fatty 
acids (Fig. 2.3A), which corresponded not only to changes in the relative abundance of 
the respective transcripts (Fig. 2.3B) but also to shifts in the amounts of isolated fatty 
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acyl-CoAs (Fig. 2.3C).   The D3 EBs showed even greater increases in the very-long-
chain (DH)Cer (Fig. 2.5 and 2.6). 
The functional significance of these differences in (DH)Cer subspecies is not 
known. However, synthesis of C16-Cer by CerS5, is elevated during apoptosis (50-52); 
in some cell types, C18-Cer is associated with cell growth control (53); and differences in 
the time course of changes in C16- versus C24-Cer have been associated with different 
phases of apoptosis (52, 54). Therefore, changes in the types of Cer backbones may play 
important roles in membrane structure and signaling during development. 
In addition to these shifts in (DH)Cer types, there were also higher total amounts 
of these compounds in R1 EBs vs mESCs (Fig. 2.7), which might participate in the 
regulation of primitive ectoderm cell polarity and/or Cer-induced apoptosis in embryonic 
development (8, 55). In contrast, the Cer monohexoses (CMH) of R1 and D3 EB were 
much lower than for mESCs, despite increases in the mRNA’s for the synthases for 
GlcCer and GalCer (Fig. 2.1), which might reflect that these intermediates are being 
utilized for the biosynthesis of more complex glycosphingolipids that are important 
during development (3, 56, 57). This would be an interesting direction for future studies. 
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Figure 2.6. Sphingolipid subspecies composition of D3 mouse embryonic stem cells at 
different timepoints during ES formation.  
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Figure 2.7.  Sphingolipid subspecies composition of R1 mouse embryonic stem cells at 
different timepoints during ES formation.   
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Transcript profiling is used widely in characterization of gene expression during 
development (58-60), however, prior to this study, the CerS gene family has not been 
included because it was only recently characterized (17). Furthermore, no previous study 
of this pathway has combined genomic analysis with measurement of the related 
downstream metabolites.  Therefore, it is hoped that this approach may be useful in 
understanding both the developmental regulation of sphingolipid metabolism and the 
roles of Cer in stem cell biology and embryonic development (61, 62). 
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CHAPTER 3 
CHARACTERIZATION OF CERAMIDE SYNTHASE 2: TISSUE 
DISTRIBUTION, SUBSTRATE SPECIFICITY AND CERS2 
KNOCKOUT MICE 
3.1 Introduction 
 The past decade has seen an upsurge of interest in sphingolipids (SLs), due 
largely to the extraordinary number of complex species that have been found in 
eukaryotes (1), as well as the involvement of the lipid backbones in signaling pathways 
as both first and second messengers (2–4). Indeed, ceramide (3) and sphingosine 1-
phosphate (S1P) (5) appear to play opposing roles in cell proliferation, migration, and 
survival, which underscores how the balance of the levels of these two lipids has 
ramifications for diverse pathological and pathophysiological processes (6–8). 
 In mammals, ceramide is synthesized by a family of six enzymes, ceramide 
synthases (CerS) 1–6 (9), each of which uses a relatively restricted subset of fatty acyl-
CoAs for N-acylation (10–12) of the sphingoid long chain base. Thus, CerS1 and CerS5, 
which are the best characterized CerS proteins, synthesize C18- and C16-ceramide, 
respectively (10,11,13,14), whereas CerS2 and -3 appear to have a broader specificity 
(15). The existence of these six CerS genes in mammals implies an important and largely 
unexplored role for ceramides containing specific fatty acids in cell physiology (9). One 
possibility is that different tissues contain ceramides with defined fatty acids, 
necessitating the presence of specific CerS in specific tissues for their synthesis. However, 
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with the exception of an early study by semi-quantitative reverse transcription-PCR (11), 
little is known about CerS tissue distribution.  
 This study describes the characterization of CerS2, which has received relatively 
little attention. We demonstrate that CerS2 mRNA occurs at much higher levels than 
most other CerS, has the broadest tissue distribution, and —in studies of cells in 
culture— synthesizes ceramides containing mainly C20–C26 fatty acids, with little or no 
synthesis of C16- and C18-ceramides. However, studies with a CerS2 null mouse that has 
been  generated by our collaborators, Dr. Tony Futerman and associates, our analyses 
suggest that CerS2 is responsible for a somewhat more narrow number of Cer 
subspecies—those with C24 + 2 carbon atoms.   
 
3.2 Experimental Procedures 
 My role on these studies was to analyze the sphingolipids that are made by these 
cells in culture and animal models.  For these analyzes, I used the same methods as 
described in Chapter 2, with minor modifications as described in figure legends and text.  
To show how these were critical for the entire study, I have included the procedures and 
results from these analyses as well as the others that were reported in the published paper 
from the cell studies (42); the data for the knockout mouse are now being prepared for 
publication. 
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3.2.1 Materials 
 D-erythro-[4,5-3H]Sphinganine was synthesized as described (16). S1P was from 
Sigma-Aldrich or from Avanti Polar Lipids (Alabaster, AL); fatty acyl-CoAs and the 
internal standards for liquid chromatography electrospray ionization tandem mass 
spectrometry (LC ESI-MS/MS) were also from Avanti. An anti-protein disulfide 
isomerase antibody was from Stressgen (Victoria, BC, Canada), and an anti-
hemagglutinin (HA) antibody was from Santa Cruz Biotechnology (Santa Cruz, CA). 
Horseradish peroxidase was from Jackson Laboratories (Bar Harbor, MA). Pfu 
polymerase was from Promega (Madison, WI) or from Stratagene (La Jolla, CA). 
TaqManTM was from Applied Biosystems (Foster City, CA). A PerfectPure RNA Kit 
was from 5Prime (Gaithersburg, MD). A Reverse-iT first strand synthesis kit was from 
Thermo Scientific (Epsom, UK). All solvents were of analytical grade and were 
purchased from Biolab (Jerusalem, Israel). 
 
3.2.2 Real-time qPCR 
 Tissues were harvested from 6- to 8-weekold mice; females were used for all 
tissues except prostate and testis. RNA was isolated using a PerfectPure RNA kit 
according to manufacturer’s instructions, which included a DNase step. cDNA synthesis 
was performed using a Reverse-iT first strand synthesis kit using random decamers with 
30-min incubation at 42 °C and then at 47 °C. cDNA generation demonstrated equivalent 
efficiency of synthesis with input RNA ranging from 15 to 500 ng per reaction (Fig. 3.1). 
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100 ng of total RNA was used to determine expression levels of mouse CerS mRNA, 
using TaqManTM analysis and a 7300 Sequence Detection System (Applied Biosystems). 
Relative CerS expression levels were determined in all tissues as compared with brain; 
quantitative analysis was assessed in brain by comparison to a standard curve generated 
via dilution of expression plasmids for each gene. To control for variability of RNA input, 
all PCR reactions were normalized to the amount of hypoxanthine guanine 
phosphoribosyltransferase 1 mRNA. Primer/probe sets for CerS1 (Mm00433562_m1), 
CerS2 (Mm00504086_m1), CerS4 (Mm01212479_m1), CerS5 (Mm00510996_g1), and 
CerS6 (Mm00556165_m1), and for hypoxanthine guanine phosphoribosyltransferase 1 
(Mm00446968_m1) were pre-validated sets obtained from Applied Biosystems. CerS3 
was custom ordered from Applied Biosystems and designed to span exon 2 and exon 3 
(Locus DQ646881). Oligonucleotides used for generation of qPCR templates are given in 
Table 3.1.  
 
3.2.3 Short Interfering RNA (siRNA) 
 siRNAs were subcloned into the pSUPER vector according to the manufacturer’s 
instructions (OligoEngine, Seattle, WA). Two siRNA targets were chosen for CerS2: 
siCerS2i, 5’-AAGCAGGTGGAAGTAGAGCTTTT-3’, and siCerS2ii, 5’-
AAGCCAGCTGGAGATTCACATTT-3’. The sequences were chosen because they 
recognize all known CerS2 isoforms (9) and do not recognize other CerS genes. CerS2 
knockdown was accomplished by transfecting Hek cells with the pSUPER vector using 
the calcium phosphate method. After various times of incubation, total RNA was 
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extracted using the RNeasy Mini Kit (Qiagen). Reverse transcription was performed 
using the EZ-First strand cDNA synthesis kit (Biological Industries, Beit Haemek, Israel), 
and PCR was performed using the primers listed in Table 3.1.  
Table 3.1. Primers used in the current study 
Gene Sequence Tm 
[°C] 
Cycles
Oligonucleotides used for generation of qPCR templatesa 
CerS1 Sense-ACAGCCAAGCCCTGCAAA 
Anti-sense-TCCACCACCATGTCTTCGTA 
60 35 
CerS2 Sense-GGCGCTAGAAGTGGGAAAC 
Anti-sense-TCGAATGACGAGAAAGAGCA 
60 35 
CerS3 Sense-GCTACACCTCTAGCAAATGCAC 
Anti-sense-ATCTTTCAACCTGGCGCTCT 
60 30 
CerS6 Sense-TTAATCATCCACGGAACAAGGACCAGTG 
Anti-sense-TTAATCATCCACGGAACAAGGACCAGTG 
55 30 
Primers used to clone CerS2 and for site-directed mutagenesis of CerS2b 
CerS2-HA Primer A, CCCAAGCTTATGCTCCAGACCTTGTAT 
(Hind3) 
Primer B, 
CCGGAATTCTCATCAAGCGTAATCTGGAACATC 
GTATGGGTAGTCATTCTTACGATGGTT (EcorI) 
48 30 
CerS2 
R230A 
 
Primer C, 
CAATTACATCGCAGCTGGGACTCTAATCATGGC 
Primer D, 
AGTCCCAGCTGCGATGTAATTGGCAAACCAG 
54/62 5/30 
CerS2 
R325A 
Primer E, 
TCATTTTGGCCATGGCCCACAAGTTCATAA 
Primer F, GCCATGGCCAAAATGAGGTAGGCCCAG 
54/62 5/30 
Primers used for mRNA expression analysis after siRNA treatment 
CerS2 5’GCTGGAGATTCACATTTTAC 
5’-GAAGACGATGAAGATGTTGT 
50 25 
GADPH 5’-TTAGCACCCCTGGCCAAGG 
5’-CTTACTCCTTGGAGGCCATG 
50 25 
a Oligonucleotides were used to generate templates for calibration of the qPCR reactions 
(see Fig. 3.1). 
b Primers A and D were used for amplification of the N terminus of the R230 construct 
and primers B and C for the C terminus. Primers A and F were used for amplification of 
the N terminus of the R325 construct and primers B and E for the C terminus. In the 
second step, the two fragments were annealed using an additional touch-up PCR step. 
Annealing temperatures of 54 °C were used for the first 5 cycles, and a temperature of 
62 °C for the next 30 cycles. 
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Figure 3.1. qPCR assays are linear over a wide range of RNA and cDNA concentrations. 
a-b) To validate real time PCR assays, a first step is to determine the amount of total 
RNA used in the cDNA synthesis reactions that is linear with respect to conditions for 
each primer and probe set. Taqman assays for the CerS and endogenous genes are linear 
from 15-500 ng total RNA used per cDNA reaction, with 2 μl of each reaction used per 
20 μl PCR reaction. In addition, the ratio of endogenous gene to CerS genes is not 
changed over this range of total RNA. c-d) Another step to validate real time PCR assays 
is to determine the amount of cDNA that can be used within each reaction. cDNA was 
synthesized with 100 ng total RNA from whole mouse brain. Various amounts of cDNA 
was used in each reaction. Taqman assays for the CerS and endogenous genes are linear 
from 0.5-4 μl per 20 μl PCR reaction. At 6 μl per 20 μl PCR reaction the assays are no 
longer linear nor does the ratio of CerS to endogenous gene remain constant. Data is a 
representative experiment performed in duplicate. 
 85
3.2.4 Cell Culture and Transfection 
 Human embryonic kidney cells (Hek 293) were grown in Dulbecco’s modified 
Eagle’s medium supplemented with 10% fetal calf serum, 100 IU/ml penicillin, and 100 
µg/ml streptomycin. Hek 293 cells were transfected with human CerS genes using the 
calcium phosphate method (0.25 µg of plasmid per cm2 of culture dish), which gave ~ 
90% transfection efficiency. Human CerS genes (17) in a pCMV vector, with an N 
terminus FLAG tag, were obtained from Dr. Richard Kolesnick (Sloan Kettering 
Institute). CerS2 was subsequently subcloned into a pcDNA3 vector containing an HA 
tag, which was located at the C terminus (CerS2-HA). Site-directed mutagenesis of 
CerS2-HA was performed using 2-Step PCR and Touch-up cycling conditions. 
 
3.2.5 Liquid Chromatography Electrospray Inonization Tandem Mass 
Spectrometry 
 SL analyses by LC ESI-MS/MS were conducted using a PE-Sciex API 3000 triple 
quadrupole mass spectrometer and an ABI 4000 quadrupole-linear ion trap mass 
spectrometer as described previously (10,11,18,19). Hek 293 cells were transfected with 
pcDNA, human CerS2, or siRNA and after 36 h, harvested by trypsinization, collected by 
centrifugation, washed twice with ice-cold phosphate-buffered saline, and lyophilized. 
The samples were spiked with an SL internal standard mixture (Avanti Polar Lipids) then 
extracted and analyzed by LC ESI-MS/MS (10, 11, 18, 19). For tissue analyses, the 
tissues were obtained from C57BL/6 mice at 7 weeks of age and different ages of CerS2 
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knockout mice, homogenized as described above, and aliquots were lyophilized. Samples 
corresponding to 1 mg of lyophilized tissue were spiked with the SL internal standard 
mixture, extracted, and analyzed by LC ESI-MS/MS. Fatty Acyl-CoA analyses by LC 
ESI-MS/MS were performed on a 4000 QTrap triple quadrupole linear ion trap mass 
spectrometer (Applied Biosystems, Foster City, CA) as recently described (37). 
 
3.2.6 CerS Assay 
 CerS activity was assayed as described previously (10, 11, 14) using Hek 293 cell 
homogenates and 0.25 µCi of [4,5-3H]sphinganine/15 µM sphinganine/20 µM defatted-
bovine serum albumin/50 µM fatty acyl-CoA for 20 min at 37 °C (17). Different amounts 
of protein were used for homogenates obtained from cells transfected with different CerS 
protein in order that the time of the reaction was linear with respect to protein (17), and 
different acyl-CoAs were used in accordance with the substrate specificity of each CerS 
(10–12, 14, 15) (CerS1, 100 µg of protein, C18-CoA; CerS2, 150 µg of protein, C22-
CoA; CerS3, 200 µg of protein, C24-CoA; CerS4, 200 µg of protein, C20-CoA; CerS5 
and CerS6, 50 µg of protein, C16-CoA).  
3.2.7 Immunofluorescence 
 The intracellular localization of human CerS2-HA was performed by confocal 
laser scanning microscopy as described for CerS4 and -5 (11), using Mito-Tracker Deep 
Red as a mitochondrial marker and protein disulfide isomerase as an endoplasmic 
reticulum marker. 
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3.3 Results 
3.3.1 CerS expression in mouse tissues 
 An early study examining the tissue distribution of CerS mRNA by semi-
quantitative RT-PCR suggested that each CerS has a somewhat unique tissue distribution, 
with CerS2 (trh3) mRNA the most ubiquitously expressed (11). To determine which 
CerS were expressed in different tissues, our collaborators established robust reaction 
conditions for real time quantitative PCR (qPCR), in which the reactions are linear over 8 
to 10 orders of magnitude and are >99% efficient (Fig. 3.2). Using these conditions, they 
analyzed CerS mRNA levels in 14 mouse tissues. 
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Figure 3.2. qPCR reactions for CerS mRNA are highly sensitivity and linear over 8-10 
orders of magnitude.  
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 In agreement with the earlier study (11), CerS2 is ubiquitously expressed. 
However, due to the linearity and sensitivity of qPCR, these study demonstrated that 
CerS2 mRNA expression levels are significantly higher than those of the other five CerS 
genes, in some cases as much as an order of magnitude higher (Fig. 3.3). Highest CerS2 
expression (30 to 40 molecules RNA/pg total RNA) was detected in liver and kidney (Fig. 
3.3), with lower levels (~5 molecules RNA/pg total RNA) in most other tissues. In 
contrast, CerS1 and -3 were expressed mainly in brain and skeletal muscle, and in skin 
and testis (15), respectively, and were virtually undetectable in other tissues. CerS4 was 
expressed at the highest levels in skin, leukocytes, heart and liver, and in the other tissues, 
was expressed at levels of 1 to 2 molecules/pg total RNA (Fig 3.3). CerS5 and -6 were 
expressed in most tissues, with expression levels of 1 to 3 molecules/pg total RNA (Fig. 
3.3). CerS2 expression tended to be low in tissues expressing highest levels of CerS1 or 
CerS3. 
 90
 
Figure 3.3. CerS2 is ubiquitously expressed and is highly abundant in mouse tissues.  
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3.3.2 Acyl-CoA Specificity and Intracellular Localization of CerS2 
 These studies also examined the specificity of CerS2 toward acyl-CoAs. 
Phylogenetically, CerS2 is most closely related to CerS3 (9), which was suggested to 
synthesize ceramides containing mainly C16:0 and C24:0 fatty acids (15). LC ESI-
MS/MS demonstrated, in contrast, that CerS2 uses a wider range of acyl-CoAs, 
synthesizing ceramides containing C20:0, C22:0, C24:1, C24:0, C26:1, and C26:0 fatty 
acids (Fig. 3.4A), but notably, does not synthesize ceramides containing C16:0 fatty acids 
and synthesizes only low, and statistically insignificant levels of C18:0-ceramide. In vitro 
analysis of CerS2 activity using a range of acyl-CoAs (Fig. 3.4B) was entirely consistent 
with LC ESI-MS/MS analysis. 
 To confirm the acyl-CoA specificity of CerS2, cells were transfected with two 
different siRNAs in a pSUPER vector, and compared with cells incubated with the 
pSUPER vector alone. CerS2 mRNA levels were significantly reduced 24 h after 
transfection with siCerS2ii and 72 h after transfection with siCerS2i (Fig. 3.5A). CerS 
activity, using C22:0-acyl-CoA as substrate, revealed a more rapid loss of activity after 
transfection with siCerS2ii compared with siCerS2i. Examination of levels of ceramides 
by LC ESI-MS/MS after transfection with siCerS2ii (Fig. 3.5C) was consistent with LC 
ESI-MS/MS data obtained after overexpression of CerS2 (Fig. 3.4A). Thus, CerS2 has a 
completely different profile of use of acyl-CoAs than the other CerS, using mainly 
medium- to long-chain CoAs, but is unable to synthesize C16:0- and C18:0-ceramides. 
 Similar to other CerS for which the intracellular localization has been examined 
by immunofluorescence after overexpression (10, 11), rather than by biochemical 
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isolation of mitochondrial fractions (20), CerS2 is localized to the endoplasmic reticulum 
(Fig. 3.6), with no co-localization with a mitochondrial marker (21).  
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Figure 3.4. Substrate specificity of CerS2 toward acyl-CoAs.  A, the fatty acid 
composition of ceramide was determined by LC ESI-MS/MS in mock- and CerS2-
transfected cells. Black columns are mock-transfected cells, and white columns are from 
CerS2 transfected cells. Results are means ± S.E. of 4–5 individual experiments. *, 
p<0.05. The inset shows C26:0 and C26:1 levels scaled appropriately. B, in vitro analysis 
of CerS2 activity. Results are means ± S.D. of a representative experiment performed in 
triplicate and repeated 3–4 times; *, p<0.05. 
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Figure 3.5. Effect of siRNA on mRNA expression, ceramide synthesis, and ceramide 
levels.  
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Figure 3.6. CerS2 is localized to the endoplasmic reticulum. The localization of CerS2, 
HA-tagged at the C terminus (CerS2-HA) was compared with the endoplasmic reticulum 
marker, protein disulfide isomerase, and the mitochondria-specific dye, MitoTracker. The 
merged views are shown in pseudocolor with co-localization of anti-HA and anti-protein 
disulfide isomerase in yellow. The insets show enlarged views of the areas indicated by 
the boxes. Bar, 5 µm. 
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3.3.3 Relationship between CerS mRNA Expression and Ceramide N-Acyl Chain 
Composition 
 Although CerS2 mRNA is widely distributed and found at high levels in various 
tissues (Fig. 3.3), nothing is known about how this is related to levels of expression of the 
CerS2 protein or of the relative proportions of ceramides containing C20:0-C26:0-fatty 
acids, the subspecies synthesized by CerS2 (Figs. 3.4 and 3.5). Because there are no 
antibodies currently available to mouse CerS2,3 we examined the ceramide subspecies 
distribution by LC ESI-MS/MS to determine if tissues that display high levels of CerS2 
mRNA are enriched in the corresponding ceramide subspecies in ceramides, 
sphingomyelin (SM), and monohexosylceramide (Hex-Cer) (Fig. 3.7). Comparison of the 
ceramide N-acyl chain distribution with that of the relative levels of expression of CerS 
mRNA (Fig. 3.7) reveals that the two tissues with highest CerS2 mRNA levels, kidney 
and liver, also have the highest proportions of C22- to C24-ceramides. Kidney also has 
high proportions of C22–C24 acyl chains in SM and HexCer (Fig. 3.7) as does liver, 
although the N-acyl chain composition of HexCer differs from that of ceramides and SM. 
For the other three tissues (brain, testis, and skeletal muscle), CerS2 is less prevalent than 
the mRNAs of the other CerS, and the proportions of C22-, C24-, and C24:1-ceramides 
and -SMs are correspondingly lower. Interestingly, for two of these tissues (brain and 
skeletal muscle), HexCer contains surprisingly high proportions of C22–C24-ceramides, 
                                                 
 
 
3 A Commercial antibody is available for human CerS2 but unfortunately shows no cross-
reactivity to mouse CerS2. 
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suggesting that there are factors other than the relative amounts of the CerS mRNA that 
affect the subspecies distribution, particularly in downstream complex SLs and glyco-SLs. 
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Figure 3.7. mRNA expression levels for CerS1 to -6 compared with the N-acyl chain 
distribution of ceramides, SM, and HexCer in five mouse tissues. The left-hand panel 
shows the percent distribution of CerS mRNA in the five tissues analyzed, taken from the 
data used in Fig. 3.1. The three right-hand panels show the percent distribution of acyl 
chains in ceramide, SM, and HexCer for the same tissues. The pie charts are colorcoded 
according to the specific CerS and the ceramide species that they synthesize, as shown in 
the legend. For simplicity, only the main ceramide species synthesized by each CerS are 
shown. Thus, C22, C24, and C24:1 are shown for CerS2 with C20 (which is only a minor 
species) excluded; the different ceramides made by CerS2 are indicated in the figure. For 
CerS4, only C20 is shown. Data are from three triplicate analyses from two animals. 
Levels of ceramides (in pmol/mg of protein) for each tissue are given in Table 3.2.  
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Table 3.2 Levels of ceramide, HexCer and SM are shown for five different tissues. This 
data is presented in Fig. 3.7 as a percent distribution, and are from three triplicate 
analyses from two animals. 
Acyl chain length Kidney Liver Brain Skeletal 
muscle 
Testis 
Ceramide (pmol/mg protein) 
C16:0 346 ± 41 108 ± 47 49.3 ± 7.8 24.3 ± 9.9 614 ± 178 
C18:0 26.1 ± 2.4 29.8 ± 13.7 1628 ± 477 152 ± 17 30.1 ± 7.1 
C20:0 21.6 ± 2.8 16.7 ± 7.5 39.6 ± 12.6 3.2 ± 0.6 15 ± 5 
C22:0 88.3 ± 5.3 102 ± 39 31.8 ± 6.8 9.9 ± 2.4 40.9 ± 12.1 
C24:0 99.3 ± 11.1 107 ± 34 25± 5 9.8 ± 1.8 20.3 ± 3.5 
C24:1 55.6 ± 3.7 139 ± 57 138 ± 11 16.4 ± 3.9 37.2 ± 6.4 
C26:0 1.1 ± 0.4 1.5 ± 0.5 0.7 ± 0.3 0.5 ± 0.5 50.2 ± 19.8 
C26:1 1.0 ± 0.6 1.4 ± 0.6 1.6 ± 1.1 0.8 ± 1.0 2.9 ±1.0 
Hexosylceramide (pmol/mg protein) 
C16:0 3.6 ± 1.3 16.6 ± 3.0 3.9 ± 0.7 1.1 ± 0.8 28.0 ± 5.3 
C18:0 1.0 ± 0.5 2.4 ± 0.9 75.1 ± 12.8 2.3 ± 0.4 1.5 ± 0.4 
C20:0 2.2 ± 0.3 0.3 ± 0.2 12.0 ± 4.5 2.2 ± 0.6 0.3 ± 0.2 
C22:0 4.0 ± 0.9 0.4 ± 0.2 64.3 ± 16.5 8.4 ± 2.8 0.7 ± 0.2 
C24:0 2.2 ± 0.9 0.3 ± 0.1 39.4 ±10.7 10.3 ± 2.7 0.5 ± 0.2 
C24:1 18.9 ± 4.7 1.4 ± 0.6 409 ± 100 122 ± 28 4.6 ± 1.3 
C26:0 0.2 ± 0.2 0 4.8 ± 1.5 0.4 ± 0.3 0.1 ± 0.1 
C26:1 0.6 ± 0.3 0.1 ± 0.1 4.3 ± 1.4 1.4 ± 0.6 0.1 ± 0.1 
Sphingomyelin (pmol/mg protein) 
C16:0 2510 ± 313 301 ± 17 81 ± 12 122 ± 36 2078 ± 322 
C18:0 183 ± 18 76.2 ± 5.5 1801 ± 160 363 ± 49 178 ± 21 
C20:0 260 ± 36 40.5 ± 4.2 100 ± 17 16.9 ± 1.7 49.9 ± 7.0 
C22:0 655 ±100 146 ± 21 39.1 ± 12.6 23.3 ± 2.5 76.3 ± 10.5 
C24:0 1122 ± 180 249 ± 28 112 ± 40 43.3 ± 6.4 83.6 ± 8.2 
C24:1 1972 ± 363 628 ± 45 478 ± 158 103 ± 18 265 ± 16 
C26:0 14.0 ± 1.7 2.1 ± 0.4 1.1 ± 0.3 0.6 ± 0.1 1.5 ± 0.5 
C26:1 14.3 ± 2.3 2.8 ± 0.4 4.2 ± 1.2 1.1 ± 0.2 2.8 ± 1.2 
 
3.3.4. Analysis of sphingolipid profiles in CerS2 null mice 
 To further study the role of CerS2, we have analyzed tissues from a CerS2 null 
mouse that we have received from Dr. Futerman. CerS2 null mice are born with a normal 
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Mendelian distribution but are born significantly smaller than their littlemate controls; 
they live for at least one year.  
 LC ESI-MS/MS analyses of SLs of livers derived from CerS2 null mice (-/-) 
found that very-long chain Cer with chain lengths of C22 and C24 (both C24:0 and 
C24:1) were ca. 80 ~ 99 % lower than in livers from wild type CerS2 mice (Fig. 3.8, 3.9 
and 3.10).  The C26:1- and C26-SL in CerS2 null mice livers also appeared lower than in 
wild type CerS2 mice livers, however, the amounts were very low for both and difficult 
to quantify accurately.  The very-long chain Cer backbones were also undetectable or 
barely detectable in SM and HexCer from the CerS2 null mice.  In contrast, the CerS2 
null mice livers had higher C16-Cer and C16-SLs than the wild type mice, with increases 
of up to 10-fold (Fig. 3.8, 3.9 and 3.10).  
 Interestingly, livers from wild type mice displayed changes in the amounts of 
some Cer subspecies over developmental time:  decreasing amounts of C16-Cer and 
increasing amounts of C22-Cer (Fig. 3.8). The latter might imply that CerS4, which is 
selective for C20 + 2 carbon atom-Cer synthesis might be involved, which could be of 
interest to study in the future.  In contrast, the amounts of C24:1- and C24-Cer increased 
after 30 days (Fig. 3.8).  
 In addition, Sa levels were very low in wild type mice, but started high in null, 
and then highly increased. Sa levels were ~30-fold higher on day 30 and 95-fold higher 
on day 120 in CerS2 null mice (Fig. 3.11). Moreover, there were no differences in acyl 
CoA levels between livers from wild type mice and CerS2 null mice (Fig. 3.12). Note 
that livers from different mice have shown the similar N-acyl chain distributions of SL, 
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although, in this thesis, we show one set of data analyzed by LC ESI-MS/MS from one 
animal on developmental time and that results are means ± S.D. of a representative 
experiment performed in triplicate. 
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Figure 3.8. Ceramide profiles in livers derived from wild type mice (+/+, blue) and CerS2 
null mice (-/-, black) at ages (days).   
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Figure 3.9. Ceramide monohexoses profiles in livers derived from wild type mice (+/+, 
blue) and CerS2 null mice (-/-, black) at ages (days).   
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Figure 3.10. Sphingomyelin profiles in livers derived from wild type mice (+/+, blue) and 
CerS2 null mice (-/-, black) at ages (days).  
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Figure 3.11. Sphingoid bases (sphingosine and sphinganine) profiles in livers derived 
from wild type mice (+/+, blue) and CerS2 null mice (-/-, black) at ages (days).   
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Figure 3.12. Fatty acyl-CoA profiles in livers derived from wild type mice (+/+, blue) and 
CerS2 null mice (-/-, black) at ages (days).   
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3.4 Discussion 
 Since the initial molecular identification of CerS1 (uog1) (10) as a ceramide 
synthase, considerable effort has been invested in characterizing the six members of this 
mammalian gene family. Most studies to date have focused on the acyl-CoA specificity 
of the proteins (10–12, 15). However, with the exception of one in vitro ceramide 
synthase assay reported in Mizutani et al. (12), CerS2 has not been well characterized. 
We now rectify this situation and report the surprising results that CerS2 mRNA is highly 
abundant, that CerS2 displays a remarkable fatty acyl-CoA specificity, showing 
essentially no activity with C16-CoA, very low or no activity with C18-CoA, and less 
selectivity among longer chain fatty acyl-CoAs when assayed in cells in culture, but a 
C24 + 2 specificity in the studies with CerS2 null mice. Together, these results suggest 
important differences in both the biology of CerS, and in their biochemical modes of 
regulation. 
 The distinctiveness of CerS2 from other CerS can also be ascertained from study 
of its genomic organization (Table 3.3). CerS2 has a compact gene size, a low number of 
introns, short 5’- and 3’-UTRs, with a large percentage of surrounding chromosomal 
sequence containing CpG and Alu elements, and contains a low percentage of 
retrotransposon LINE-1s. Further, our collaborator has noted that CerS2 is located within 
chromosomal regions that are replicated early within the cell cycle (I. Simon, Hebrew 
University of Jerusalem, Israel, personal communication). These genomic features are 
characteristic of a “housekeeping” gene; indeed, predictive analysis performed using 
multiple parameters (27–29) supports the possibility that the CerS2 gene is a genuine 
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housekeeping gene (Table 3.3). Interestingly, no other CerS genes display these 
characteristics. 
 
Table 3.3 CerS2 has genomic features characteristic of a housekeeping gene. 
Gene size and length of introns were calculated by examination of each gene using the 
UCSC genome browser. The presence or absence of Line-1 and Alu elements were 
analyzed in chromosomal regions 100,000 bp upstream and downstream using the 
RepeatMasker program that screens DNA for interspersed repeats and low complexity 
sequences. CpG elements in the same region were analyzed using the CpG report 
program, which searches for regions of 50 bp or longer with >50% GC content. 
Gene Species Accession # Gene 5’-
UTR
3’-
UTR 
Intron Line-
1 
Alu CpG 
                                               Length (bp)                                           % 
CerS1 Mouse 
Human 
NM_138647 
NM_021267 
14,084
27,593
30
72
333
1,433
12,668 
25,035 
0.41 
1.78 
8.92
32.78
5.79
13.00
CerS2 Mouse 
Human 
NM_029789 
NM_181746 
8,315
9,791
95
387
777
974
6,300 
7,287 
1.58 
5.68 
11.52
37.29
4.52
8.91
CerS3 Mousea 
Human 
DQ35808 
NM_178842 
57,667
144,325
7
424
0
2,300
56,545 
140,432 
12.91 
24.39 
1.66
8.70
2.27
4.78
CerS4 Mouse 
Human 
NM_026058 
NM_024552 
32,254
53,046
88
280
1,977
309
29,007 
51,272 
34.07 
3.38 
2.44
50.26
1.84
10.83
CerS5 Mouse 
Human 
NM_028015 
NM_147190 
36,924
36,774
136
13
629
326
34,914 
35,483 
0.57 
7.32 
6.99
1.96
6.59
6.60
CerS6 Mouse 
Human 
NM_172856 
NM_203463 
249,732
253,782
79
69
2,694
1,065
245,804 
249,797 
12.89 
1.43 
1.71
9.56
1.08
1.06
a The CerS3 mouse sequence is currently incomplete and the reported sequence does not 
include all UTRs. 
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 Classically, a housekeeping gene is defined as a gene with consistent levels of 
expression from tissue to tissue and that encodes a protein that is generally involved in 
routine cellular metabolism. However, the advent of qPCR and microarray analysis has 
indicated that housekeeping genes can display considerable variation in expression levels 
in tissues and can respond to stimuli (30, 31). 
 The fact that CerS2 fulfils many of the genomic criteria of a housekeeping gene 
does not necessarily mean that it is a housekeeping ceramide synthase. However, some of 
the intracellular signaling functions of ceramides have been ascribed to C16-ceramide 
(reviewed in Ref. 9), which, conspicuously, CerS2 does not synthesize. The broad tissue 
distribution of CerS2 might imply that ceramides synthesized by CerS2 are intermediates 
in SL metabolism in most cells, whereas other CerS, which are found at lower expression 
levels and which synthesize a more restricted subset of ceramide acyl chains (i.e. CerS5, 
which synthesizes C16-ceramide (11), and CerS1, which synthesis in specific tissues 
under specific physiological conditions, or after certain stimuli, such as in apoptosis or 
cell proliferation (13, 32).  
 Indeed, our data imply that there are multiple ways to regulate CerS activity and 
expression, and to regulate levels of ceramides containing specific acyl chains. Thus, 
although there is a relatively good correlation between CerS2 mRNA expression and 
levels of C20–26-ceramides, C20–26-SM and C20–26-HexCer in kidney, there is a 
remarkable difference between the acyl chain composition of SM and HexCer in liver, 
even though both tissues contain high levels C20–26-ceramide, and high levels of CerS2 
expression. Likewise, levels of C16-ceramide, C16-HexCer, and C16-SM are high in 
testis, even though expression of CerS3 mRNA is highest in this tissue; CerS3 
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synthesizes mainly long chain ceramides, but perhaps also C16-ceramide (15). C18-
ceramide and C18-SM levels are high in brain and skeletal muscle, which contains 
correspondingly high levels of CerS1 mRNA (33), but HexCer contains mainly longer 
acyl chain ceramides in these tissues. This clearly demonstrates multiple levels of 
regulation of ceramide biosynthesis, which most likely also includes the availability of 
the co-substrate, fatty acyl-CoAs, subspecies-selective trafficking (because CERT, a 
protein involved in ceramide transport from the endoplasmic reticulum for SM synthesis 
in the Golgi apparatus (34), has a defined specificity toward different acyl chain 
ceramides (35)), and factors such as the degree to which ceramide remodeling may occur 
in at the Golgi apparatus, where ceramidases have been found (36). It is also possible that 
there is channeling of intermediates into specific ceramides and downstream SLs, in 
analogy to findings with CerS1 (10), in which C18-ceramide was channeled into neutral 
glyco-SLs compared with acidic glyco-SLs (gangliosides) and SM. 
 The fatty acid chain specificity of CerS2 was generally confirmed by analysis of 
the livers from CerS2 null mice, but was somewhat narrower (i.e., only showing changes 
in C24 + 2 carbons in chain length). This might be due to changes in other CerS in the 
cell culture experiments where CerS2 was elevated by overexpression or decreased with 
siRNA.  Indeed, in the CerS2 null mice, C16-Cer and Sa levels were increased in CerS2 
null mice, and in other experiments if this laboratory (Ying Liu, personal communication), 
changing other aspects of sphingolipid biosynthesis has been found to induce CerS1.  The 
differences might also be due to the types of fatty acyl-CoAs that are available, however, 
the analysis of the fatty acyl-CoAs in livers from CerS2 null mice did not show that they 
lack C20-fatty acyl-CoA’s (Fig. 3.12). 
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 What are some of the additional issues that should be kept in mind when thinking 
about what might cause these changes in the backbone composition of sphingolipids (i.e., 
increases in C16- and decreases in C24 + 2-Cer) when CerS2 is eliminated?  There are a 
number of possibilities, for examples: (i) it has been noted that all CerS have similar Km 
values toward Sa (17), therefore, when one is eliminated, Sa will probably be utilized by 
the others until all are saturated with substrate (which may explain why Sa is elevated, 
too); (ii) there might be changes in fatty acid metabolism so that the amounts of the co-
substrates change (for example, for palmitoyl-CoA to increase), however, this is unlikely 
since we did not observe differences in fatty acyl-CoA (Fig.3.12), (iii) it is possible that 
downstream enzymes that utilize C24-Cer are not able to accommodate alternative 
substrates (i.e., C16-Cer), so the latter pile up—this is unlikely because all of the 
sphingolipids that we have examined contain both long-chain and very-long-chain Cer, 
albeit often in varying ratios; (iv) it is possible that the knockout of CerS2 and changing 
the types of sphingolipids leads to cell stress, which has been noted to induce C16-Cer 
production (38 ); and (v) it is possible that the change in sphingolipid composition affects 
the production of stress mediators such as interleukins and TNF-α by inflammatory cells, 
which have been found to induce C16-Cer production from SM by activation of ASMase 
(39, 40, 41). Indeed, liver cells have been one of the models where TNF-α increased C16-
ceramide content.   These should be explored in future studies of these CerS2 null mice. 
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CHAPTER 4 
    CERAMIDE SYNTHASE INHIBITION BY FUMONISIN B1 
CAUSES ACCUMULATION OF 1-DEOXYSPHINGANINE: A 
NOVEL CATEGORY OF BIOACTIVE 1-DEOXYSPHINGOID 
BASES AND 1-DEOXYDIHYDROCERAMIDES BIOSYNTHESIZED 
BY MAMMALIAN CELL LINES AND ANIMALS. 
4.1 Introduction 
 Fumonisins (FB) cause diseases of horses, swine, and other farm animals and are 
regarded to be potential risk factors for human esophageal cancer (1) and, more recently, 
birth defects (2). Studies of this family of mycotoxins, and particularly of the highly 
prevalent subspecies fumonisin B1 (FB1) (reviewed in Refs. 1 and 2), have established 
that FB1, is both toxic and carcinogenic for laboratory animals, with the liver and kidney 
being the most sensitive target organs (3, 4). Other FB are also toxic, but their 
carcinogenicity is unknown.  
 FB are potent inhibitors of ceramide synthase(s) (CerS) (5), the enzymes 
responsible for acylation of sphingoid bases using fatty acyl-CoA for de novo 
sphingolipid biosynthesis and recycling pathways (6). As a consequence of this inhibition, 
the substrates sphinganine (Sa) and, usually to a lesser extent, sphingosine (So), 
accumulate and are often diverted to sphinganine 1-phosphate (Sa1P) and sphingosine 1-
phosphate (S1P), respectively (7), while the product N-acyl sphinganines 
(dihydroceramides), N-acyl sphingosines (ceramides, Cer), and more complex 
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sphingolipids decrease (5, 7). This disruption of sphingolipid metabolism has been 
proposed to be responsible for the toxicity, and possibly carcinogenicity, of FB1, based on 
mechanistic studies with cells in culture (5, 7–9). This has been borne out by a number of 
animal feeding studies that have correlated the elevation of Sa in blood, urine, liver, and 
kidney with liver and kidney toxicity (4, 7, 10, 11). 
 Most of the mechanistic studies have focused on the accumulation of free Sa and 
other sphingoid bases, because these compounds are highly cytotoxic, although the large 
number of bioactive metabolites in this pathway make it likely that multiple mediators 
may participate (7, 9). Nonetheless, inhibition of serine palmitoyltransferase (SPT), the 
initial enzyme of de novo sphingolipid biosynthesis, reverses the increased apoptosis and 
altered cell growth induced by FB1 treatment (12–19). Therefore, it is likely that these 
effects of FB1 are due to the accumulation of cytotoxic intermediate(s) rather than 
depletion of downstream metabolites, because the latter also occurs when SPT is 
inhibited. 
 In studies of the effects of FB1 on the renal cell line LLC-PK1 (20) (R. Riley, 
unpublished observations), we have noted that in addition to the elevation of Sa and So, 
there is a large increase in an unidentified species that appears to be a sphingoid base. 
The evidence for this is because it is extracted by organic solvents, derivatized with 
ortho-phthalaldehyde (OPA), and eluted from reverse-phase liquid chromatography (LC) 
in the sphingoid base region. Herein we report: (i) the isolation and characterization of 
this novel sphingoid base as 1-deoxysphinganine (1-deoxySa); (ii) that its origin is the 
utilization of alanine instead of serine by SPT as well as that the N-acyl-derivatives of 1-
deoxySa (1-deoxydihydroceramides (1-deoxyDHCer)) are normally found in mammalian 
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cells; (iii) that 1-deoxySa has cytotoxicity comparable to other sphingoid bases elevated 
by FB1; (iv) that 1-deoxySa is not only elevated in cells in culture but also in tissues of 
animals exposed to dietary FB1 and, therefore, might contribute to diseases caused by 
these mycotoxins; and (v) that the type of sphingoid base is affected dramatically by 
amino acid supplementation. 
 
4.2 Experimental Procedures 
4.2.1 Materials 
 Pig kidney epithelial cells (LLC-PK1; CL 101), African green monkey kidney 
cells (Vero cells; CCL 81), and the human prostate cancer cell line (DU-145, HTB-
81TM) were from the American Type Culture Collection (ATCC, Manassas, VA). The 
LY-B and LY-B-LCB1 cells were a generous gift from Ken Hanada (21). P53N5-W 
mice, 5–7-week-old, were purchased from Taconic Farms, Inc. (The P53N5 strain was 
derived originally from the C57BL/6 mouse strain). 
 FB1 used in the in vitro studies was prepared and purified (>95% purity) as 
described in Meredith et al. (22) (establishing that the impurities were primarily other 
FBs and FB dimers) or for the experiments specified were purchased from Biomol 
(Philadelphia, PA). FB1 used in the mouse feeding study was supplied by Dr. Marc 
Savard (Agriculture and Agri-Food Canada, Ottawa, ON, Canada). Myriocin was 
prepared as described in Riley and Plattner (23). Free sphingoid bases, sphingoid base 1-
phosphates, and the internal standard mixture for sphingolipids (Sphingolipid Mixture II, 
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LM-6005) were purchased from Avanti Polar Lipids (Alabaster, AL) except for D-rythro-
C16-sphingosine, which was from Matreya (Pleasant Gap, PA). 1-DeoxySa was initially 
synthesized by minor modifications of a recently developed method for the synthesis of 
So (24) and has subsequently become available commercially from Avanti Polar Lipids. 
 Dulbecco’s phosphate-buffered saline (PBS), Hanks’ balanced salt solution, and 
Minimal Essential Medium (MEM, Invitrogen catalogue no. 61100-061) were obtained 
from GIBCO Invitrogen. Eagles Minimal Essential Medium, Dulbecco’s modified 
Eagle’s medium (DMEM), Ham’s F12, fetal calf serum (FCS), and trypsin/EDTA were 
obtained from ATCC. L-[U-13C]Alanine, L-[U-13C]serine, and [U-13C]palmitic acid (all 
≥98% purity) were purchased from Cambridge Isotope Laboratories, Inc. Preparative C18 
bulk packing material (55–105 µm) was purchased from Waters (Waters Corp., Part No. 
WAT010001). Acetonitrile (Burdick&Jackson) and water (J. T. Baker) were high 
performance LC (HPLC) grade and formic acid (>95%; Sigma-Aldrich) and all other 
reagents and chemicals were of analytical grade or better and were from various 
commercial suppliers. 
 
4.2.2 Cell Culture 
 LLC-PK1 cells were grown and maintained in 25-cm2 culture flasks containing 
DMEM/Ham’s F12 (1:1) with 5% FCS at 37 °C and 5% CO2. For experiments using 
confluent cultures of LLC-PK1 cells, the cells were seeded at ~15,000 to 30,000 viable 
cells/cm2 in 8-cm2 dishes and then allowed to attach and grow to at least 90% confluence 
(3–5 days) prior to addition of test agents added directly to the media without addition of 
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fresh growth medium. For experiments measuring effects on rapidly proliferating cells, 
the LLC-PK1 cells were seeded at ~2,500 viable cells/cm2 in 8-cm2 dishes and allowed to 
attach and grow for 2 to 3 days (until ~30% confluent) prior to addition of fresh growth 
medium containing the various test agents. The seeding density was chosen so that cell 
number in control cultures increased linearly over the entire experimental time course. 
Vero cells were grown and maintained in 25-cm2 culture flasks containing Eagles MEM 
with 10% FCS at 37 °C and 5% CO2. All experiments with Vero cells used rapidly 
proliferating cells that had been subcultured from confluent cultures at a 1:36 split ratio 
into 8-cm2 dishes. This split ratio resulted in cultures that were ~30% confluent after 24 h. 
The DU-145 cells were grown in Eagles MEM and 10% FCS at 37 °C and 5% CO2 as 
described in the technical literature from the ATCC. The LY-B and LY-B-LCB1 cells 
were cultured in medium containing DMEM/Ham’s F12 (1:1) with 5% FCS at 37 °C and 
5% CO2, essentially as described in Ref. 21.  
 After treatments, cells were washed twice with ice-cold PBS, the dishes placed on 
ice, and cells removed from the surface of the dishes using a rubber scraper. The cells 
detached by scraping were collected in polypropylene tubes and pelleted by centrifuging 
at 4 °C. The PBS was removed, and the cells frozen at ~20 °C. Except where noted, cell 
extracts were normalized by protein amounts, which were determined by the Lowry 
method (25) and a commercially available kit (Pierce® BCA Protein Assay Kit, Thermo 
Scientific Pierce) using bovine serum albumin (BSA) as the standard. 
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4.2.3 Sphingolipid Extraction and Analysis 
 A number of independent methods were used to characterize the sphingolipids to 
provide confirmation of the findings, and the specific method is indicated in the text and 
figure legends: 1) Free sphingoid bases were extracted from the cells and quantified by 
high performance LC (HPLC) and fluorescent detection of the OPA derivatives using 
C20-sphinganine (C20 Sa) as an internal standard according to Riley et al. (26). 2) Free 
sphingoid bases and sphingoid base 1-phosphates were also analyzed (in experiments 
with proliferating and confluent cultures of LLC-PK1 cells, Vero cells, and homogenates 
of mouse liver and kidney) by LC tandem linear-ion trap electrospray ionization mass 
spectrometry (LC ESI-MS/MS) using the method of Zitomer et al. (27) except that 
instead of extracting pulverized freeze-dried tissues, either fresh liver or kidney 
homogenates (10–20 mg/100 µl phosphate buffer) or cultured cells (50–100 µg protein) 
were extracted with C16-So and C17-S1P as internal standards. 3) Free sphingoid bases 
and N-acyl-derivatives were analyzed by minor modifications of published methods (28) 
to detect compounds with and without the 1-hydroxyl group based on their resolution by 
LC. For 1-deoxySa, the precursor ion m/z 286.4 and product ion m/z 268.4 (-H2O) in 
positive ionization mode were followed. (Note: these overlap with ions from other 
sphingoid bases, such as d17:1; however, these compounds are resolved by LC as 
described below.) For N-acyl-1-deoxySa, the cell and tissue extracts were first scanned 
for precursors for m/z 268.4 to identify which N-acyl-derivatives were present. Then they 
were analyzed by LC ESI-MS/MS using multiple reaction monitoring with Q1 and Q3 set 
to pass the following precursor and product ions for the designated N-acyl-1-deoxySa. 
The abbreviations connote the sphingoid base, m18:0, and fatty acid chain length and 
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number of double bonds using standard nomenclature (28): 524.7/268.4 (m18:0/C16:0), 
552.7/268.4 (m18:0/C18:0), 580.7/268.4 (m18:0/C20:0), 608.8/268.4 (m18:0/C22:0), 
634.9/268.4 (m18:0/C24:1), 636.9/268.4 (m18:0/C24:0), 662.9/268.4 (m18:0/C26:1), and 
664.9/268.4 (m18:0/C26:0). The LC ESI-MS/MS of the free sphingoid bases was 
conducted using reverse phase LC (Supelco 2.1 X 50 mm Discovery C18 column, Sigma) 
and a binary solvent system at a flow rate of 0.6 ml/min delivered by a Shimadzu LC-10 
AD VP binary pump system coupled to an ABI 4000 QTrap (Applied Biosystems, Foster 
City, CA). The binary system began with equilibration of the column with a solvent 
mixture of 60% mobile phase A (CH3OH/H2O/HCOOH, 58/41/1, v/v/v, with 5mM 
ammonium formate) and 40% mobile phase B (CH3OH/HCOOH, 99/1, v/v, with 5 mM 
ammonium formate), sample injection (typically in 50 µl of the same mixture), elution 
with this mixture for 1.3 min followed by a linear gradient to 100% B over 2.8 min, and 
then a column wash with 100% B for 0.5 min followed by a wash and re-equilibration 
with the original A/B mixture before the next run. The elution times were 2.1 min for 
C17 So (internal standard), 2.4 min for C18 So, 2.6 min for C18 Sa, and 2.8 min for C18-
1-deoxySa, with all having baseline resolution. 
 The N-acyl-derivatives were analyzed by normal phase LC (Supelco 2.1 X 50 mm 
LC-NH2 column) at a flow rate of 0.75 ml/min and an isocratic solvent system 
(CH3CN/CH3OH/CH3COOH/CH3(CH2)3OH/H2O, 95/3/1/0.4/0.3, v/v with 5 mM 
ammonium acetate) delivered by a Perkin Elmer Series 200 MicroPump system coupled 
to a PE Sciex API 3000 triple quadrupole mass spectrometer (Applied Biosystems, Foster 
City, CA). Using these LC conditions, the 1-deoxydihydroceramides (1-deoxyDHCer) 
elute together at 0.3 min and are resolved from ceramides (Cer), which elute at 0.37 min. 
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The settings for the mass spectrometry were optimized for each category of compounds 
as described previously (28). Quantitation was based on spiking the original extract with 
the sphingolipid internal standard mixture from Avanti Polar Lipids and comparison of 
the areas for m18:0 with d17:0 (which were approximately the same based on 
comparison of d17:0 with synthetic m17:0) and for N-acyl-1-deoxySa, the C12-Cer 
internal standard . Therefore, although these are close approximations, absolute 
quantitation will require the availability of MS internal standards for these specific 
compounds. 4) High resolution accurate mass MS was conducted on an ABI Q-Star 
(Applied Biosystems, Foster City, CA) using samples in methanol infused via a TriVersa 
nanomate (Advion Biosciences, Ithaca, NY) using a D-chip at 1.5 kV and a gas pressure 
of 0.2 psi. A total of 30 scans were averaged. 
 To obtain sufficient quantity of the unidentified sphingoid base for chemical 
characterization, the free sphingoid bases were partially purified from thirty 75-cm2 
flasks of confluent cultures of LLC-PK1 cells that had been treated with 35 µM FB1 for 
120 h. The cells were scraped and pooled in a single glass tube, and the free sphingoid 
bases were extracted and treated with 0.1 M KOH in methanol to decrease interference 
from glycerolipids as described by Riley et al. (26). The extracted sphingoid bases were 
dissolved in a small volume of CH3CN:H2O:HCOOH (49.5:49.5:1, v/v/v) and loaded on 
a minicolumn of preparative C18 packing material (5 mm X 60 mm) equilibrated with the 
same mobile phase. Free sphingoid bases were eluted by increasing the percentage of 
acetonitrile, and the fractions that were enriched in the unidentified sphingoid base were 
identified by LC linear ion trap-ESI-MS/MS, pooled, dried under nitrogen, and stored at 
~80 °C for later analysis. 
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4.2.4 Analysis of Stable Isotope-labeled Sphingoid Bases using L-[U-13C]Alanine and 
L-[U-13C]Serine 
 Vero cells at ~30% confluence in 8-cm2 culture plates were incubated in MEM 
(Invitrogen 61100-061 without serine or alanine) with 2% FCS and 7 amino acid 
supplements (with 16 dishes per supplement): (i) 100 µM L-serine (natural abundance 
13C) + 100 µM L-alanine (natural abundance 13C), (ii) 100 µM L-serine + 100 µM L-[U-
13C]alanine, (iii) 100 µM L-serine + 300 µM L-[U-13C]alanine, (iv) 100 µM L-serine + 
500 µM L-[U-13C]alanine, (v) 100 µM L-[U-13C]serine + 100 µM L-alanine, (vi) 300 µM 
L-[U-13C]serine + 100 µM L-alanine, and (vii) 500 µM L-[U-13C]serine + 100µM L-
alanine. After 24 h in culture, half of the dishes in each group were administered sterile 
FB1 for a final concentration of 35µM. After 48 h of additional incubation, half of the 
dishes in each group were used for sphingolipid analysis and half for protein assays. This 
experiment was repeated twice. Analysis of the sphingolipids in the extracts included m/z 
for the 12C-labeled products and the [13C] masses of relevant compounds (mass of [12C] 
parent ion + 2 mass units resulting from incorporation of 2 carbons from the L-[U-
13C]amino acid with the third 13C-labeled carbon lost as 13CO2). 
 
4.2.5 Analysis of 1-DeoxySa and Metabolites in LY-B and LY-B-LCB1 Cells 
 These cell lines were plated in 100-mm culture dishes to ~50% confluence, and 
then new medium (a 1:1 mixture of DMEM and Ham’s F12 media with 10% FCS) 
containing 0.1 mM [U-13C]palmitic acid bound to fatty acid-free BSA (as a 1:1 molar 
complex) was added. After 24 h, the lipids were extracted as described previously (28) 
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and analyzed for the 12C and 13C-labeled sphingolipids (with the latter having a M + 16 or 
M + 32 m/z offset from the 12C-species) using LC ESI-MS/MS as described above. 
 
4.2.6 Effect of Sa and 1-DeoxySa on Cell Growth, Accumulation of Sphingoid Bases, 
Sphingoid Base 1-Phosphates, Cer, and 1-DeoxyDHCer 
 As described previously (8, 13), LLC-PK1 cells were grown in 8-cm2 dishes to 
~30% confluence. Then Sa or 1-deoxySa was added as the 1:1 (mol/mol) complex with 
fatty acid-free BSA with or without addition of FB1 (dissolved in water) at the 
concentrations described in the text. After 48 h, cell protein was measured (25) for the 
attached cells, which we have determined to be linearly related to cell number [µg protein 
= 1.63 + 3.29 X (viable cells X 10-4), r2 = 0.96, n = 53] (8). All experiments were 
conducted with DMEM/Ham’s F12 plus 5% FCS. The effect of treatments on the 
detachment of cells was determined by collecting the medium and pelleting the detached 
cells for a separate analysis of the protein amounts. In earlier studies, we have shown that 
both FB1 and free Sa inhibit cell growth and increase the number of detached cells, which 
are dead, based on uptake of trypan blue and lactate dehydrogenase release (8, 13, 15). A 
duplicate set of dishes (n = 3/treatment) was collected for determining changes in 
endogenous sphingoid bases, sphingoid base 1-phosphates, Cer, and 1-deoxyDHCer by 
LC-ESI-MS/MS as described previously. 
 The effects of 1-deoxySa and Sa on DU-145 cells were examined by culturing the 
cells to ~25–50% confluence in 24-well dishes, addition of the sphingoid base as a 1:1 
(mol:mol) complex with fatty acid-depleted BSA (sterilized by filtration), incubation for 
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24 h, and then assessment of cell viability using the WST-1 Cell Proliferation Reagent 
(Roche Applied Science) following the manufacturer’s instructions. 
 
4.2.7 Analysis of 1-DeoxySa in Mice Fed FB1 
 Upon receipt, mice were housed individually under conditions meeting the 
requirements of the Canadian Council for Animal Care. Similar to the FB feeding 
protocols described by Gelderblom et al. (29), male mice (n 10) received a modified 
AIN 76A diet supplemented with 0 –50 mg FB1/kg for 26 weeks, and then were killed 
under isoflurane anesthesia by cardiac puncture. Liver and kidney tissues were removed 
as quickly as possible, flash-frozen in liquid N2, and stored at ~80 °C until used for 
sphingolipid analysis. 
 
4.2.8 Synthesis of N-Acyl-1-Deoxysphinganine 
 Two internal standards were synthesized for mass spectrometric characterization 
and evaluation of LC mobility:  N-palmitoyl- and N-lignoceroyl-1-deoxysphinganine.  
Both were made by the coupling of the fatty acid using the N-hydroxysuccinimide ester.  
N-palmitoyl-succinimide was available commercially but it was necessary to synthesize 
the N-hydroxysuccinimide ester of lignoceric acid following the method described in ref. 
41 and 42. Briefly, 0.4 mmol of lignoceric acid was added to a solution of N-
hydroxysuccinimide (0.4 mmol) in 1.73 mL of dry ethyl acetate followed by the addition 
of 0.4 mL of 1 M dicyclohexylcarbodiimide in dichloromethane. The reaction mixture 
was left overnight at room temperature, then centrifuged and the supernatant was 
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transferred to a new tube. The pellet was washed using 1.7 mL of ethyl acetate and 0.4 
mL of dichloromethane, centrifuged, and the supernatant was added to the first. After the 
solvent was removed by evaporation, the desired product was purified by recrystallization 
from ethanol.  The purity of the crystallized product was verified by TLC as described in 
the cited references, and by mass spectrometry.   
For the synthesis of N-lignoceroyl-1-deoxysphinganine, 34.8 µmol of 1-deoxySa 
(Avanti, AL) and 36 µmol of N-hydroxysuccinimide ester of lignoceric acid were 
dissolved in 4 mL of anhydrous tetrahydrofuran at room temperature for 18 hr. After 
drying by N2, the sample was recrystallized from methanol. The purity was checked by 
TLC and mass spectrometry.  The same procedure was used to make the N-palmitoyl- 
derivative.  
  
4.2.9 Analysis of 1-DeoxySa in SPT1/2 cells with Amino Acid Supplementation 
 SPT1/2 cells were plated in 100-mm culture dishes to ~50% confluence, and then 
new medium (a 1:1 mixture of DMEM and Ham’s F12 media with 10% FCS) containing 
0.1 mM [U-13C]palmitic acid bound to fatty acid-free BSA (as a 1:1 molar complex) was 
added. These cells were also treated with PBS (as a control), 10 mM L-serine or 10 mM 
L-alanine, and after 36 h, the lipids were extracted as described previously (28) and 
analyzed for the 12C and 13C-labeled sphingolipids (with the latter having a M + 16 or M 
+ 32 m/z offset from the 12C-species) using LC ESI-MS/MS as described above. 
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4.2.10 Analysis of 1-DeoxySa in SPT1/2 cells with 3-Phosphoglycerate 
dehydrogenase (PHGDH) and 3-Phosphoserine phosphatase (PSPH) siRNAs 
 SPT1/2 cells were grown in DMEM / F12 medium (1:1) (Gibco BRL, MD) 
supplemented with 10% fetal bovine serum (FBS), penicillin (100 U / ml) and 
streptomycin (100 μg /ml) at 37 °C in a humidified 5 % CO2 atmosphere.  For 
downregulation of PHGDH and PSPH, cells were plated in six-well plates at a density of 
1.5 x 105 per well and were transfected with ON-TARGETplus SMARTpool siRNA 
targeting human PHGDH and PSPH and appropriate control siRNA (Dharmacon, 
Lafayette, CO)., using Oligofectamine (Invitrogen) according to the manufacturer’s 
instructions. After 72 h, medium were changed to fresh costumed medium (DMEM/F12 
medium and DMEM/F12 medium without Serine/Glycine) containing 5 µM FB1 and 0.1 
mM [U-13C]palmitic acid bound to fatty acid-free BSA (as a 1:1 molar complex).  After 
24 hr incubation, the lipids were extracted as described previously (28) and analyzed for 
the 12C and 13C-labeled sphingolipids (with the latter having a M + 16 or M + 32 m/z 
offset from the 12C-species) using LC ESI-MS/MS as described above. 
 
4.3 Results 
4.3.1 FB1 Elevates Sa and a Mystery Peak in Cells 
 Shown in Fig. 4.1 are representative reverse phase HPLC profiles of the amounts 
of free sphingoid bases detected as the OPA derivatives from LLC-PK1 cells that have or 
have not been exposed to 50 µM FB1. As has been seen before (20), FB1 treatment 
increased the amount of Sa by several fold within 6 h, and by orders of magnitude after 
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48 h. In addition, a new and unidentified peak with an elution time of 12.4 min is 
noticeable after 6 h of FB1 treatment, and by 48 h, the area under the curve for this 
“mystery peak” is nearly half of that for Sa. Several additional peaks can be seen in the 
extracts from the cells treated with FB1, but these were much smaller and were not 
examined further. This phenomenon was not limited to LLC-PK1 cells because we have 
seen this mystery peak in almost every cell line that we have treated with FB1 (which 
have included Vero cells, J774 cells, HT29 cells, HEK293 cells, inter alia) (data not 
shown). 
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Figure 4.1. Representative chromatograms of lipid extracts from confluent cultures of 
LLC-PK1 cells treated with FB1 and analyzed by HPLC with fluorescence detection of 
the free sphingoid bases as the OPA derivatives using C20-Sa as an internal standard (26).  
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4.3.2 Evidence that the Mystery Peak Is an Unidentified Sphingoid Base 
 Based on its extraction by organic solvents, derivatization by OPA and LC 
mobility, it was likely that the mystery peak was a novel sphingoid base. If so, its 
production should be blocked by myriocin (also called ISP1), which is a potent inhibitor 
of SPT (30), the initial enzyme of de novo sphingolipid biosynthesis. As shown in Fig. 
4.2A, treatment of LLC-PK1 cells concurrently with myriocin blocked the FB1-induced 
elevation of Sa and the unidentified sphingoid base. Furthermore, if the cells were first 
treated with FB1 for 48 h to elevate Sa and this unidentified species (labeled as time 0 in 
Fig. 4.2B), followed by changing the cells to new medium minus FB1 with or without 
myriocin, the presence of the SPT inhibitor greatly accelerated the decline in both free Sa 
and the unidentified sphingoid base (Fig. 4.2B). The slow decline in Sa and the 
unidentified compound in Fig. 4.2B when FB1 was removed (but myriocin not added, 
hence, the cells continue to synthesize Sa de novo) suggests that partial inhibition of CerS 
persists for awhile. This is consistent with the results of an earlier study showing that the 
efflux of [U-14C]FB1 from LLC-PK1 cells was rapid (half-life 2–3 min); however, a low 
but persistent amount of [14C] remained associated with the cells (31). 
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Figure 4.2. Changes in free Sa (d18:0) and the unidentified sphingoid base (UnID) in 
confluent cultures of LLC-PK1 cells treated with FB1 and/or myriocin.  
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4.3.3 Identification of the Novel Sphingoid Base as 1-DeoxySa (m18:0) 
 The mystery peak was initially characterized by examining the partially purified 
extracts from LLC-PK1 cells (as described under “Experimental Procedures”) using a 
quadrupole-time of flight mass spectrometer (ABI QStar), which established that the 
samples contained an [M+H]+ ion of m/z 286.3123 (data not shown), for which the only 
plausible formula within 10 ppm is C18H40NO (286.3104), which is consistent with either 
a 1 or 3-deoxySa. 
 Using this information, lipid extracts from LLC-PK1 cells treated with FB1 for 25 
h (Fig. 4.3A) and 120 h (Fig. 4.3B) were analyzed by reverse-phase LC ESI MS/MS 
monitoring for the [M+H]+ ions for Sa (m/z 302.3, light gray lines) and deoxySa (m/z 
286.3, dark gray lines). Consistent with the results in Fig. 4.1, Sa eluted first (identified 
by both precursor m/z 302.3 and the known product ion spectrum for Sa, shown in the 
inset in panel A) (32) followed by deoxySa (m/z 286.3), which was more highly elevated 
at 120 h (panel B) than at 25 h (panel A), consistent with the results shown in Fig. 4.2. 
Furthermore, the product ion spectrum for the m/z 286.3 peak was consistent with a 
compound with only one hydroxyl group (i.e. a deoxySa) because it displayed loss of one 
H2O (m/z 268, inset in Fig. 4.3B), whereas Sa produced both single and double 
dehydration products (Fig. 4.3A). 
 It is also noteworthy that the product ion spectrum for the deoxySa lacks the m/z 
60.1 product ion that is obtained from fragmentation between carbons 2 and 3 of the 
sphingoid base (see inset for Fig. 4.3A) because this implies that the deoxySa lacks the 1-
hydroxyl group. To study this further, the MS3 spectra were compared for synthetic 1-
 132
deoxySa (Fig. 4.4A) and the compound partially purified from LLC-PK1 cells (Fig. 4.4B), 
and both contained the m/z 44.0 ion predicted for fragmentation between carbons 2 and 3 
of a 1-deoxySa. Therefore, based on these criteria, we tentatively identified the mystery 
peak produced by cells incubated with FB1 as 1-deoxySa. 
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Figure 4.3. Liquid chromatography of LLC-PK1 cell extracts after 24 h (A) and 120 h (B) 
of treatment with FB1 with monitoring for Sa and a novel sphingoid base by electrospray 
ionization tandem mass spectrometry.  
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Figure 4.4. Comparison of the MS3 spectra for synthetic 1-deoxySa (A) and the deoxySa 
isolated from LLC-PK1 cell extracts (B) using the method of Riley et al. (26) with 
subsequent partial purification on a minicolumn of preparative C18 packing material (5 
mm X 60 mm); fractions enriched in the deoxySa were pooled for analysis. The samples 
were introduced into a Thermo Electron Corporation LTQ XL via syringe pump and 
scanned across the mass range shown for the MS3 fragments from the single dehydration 
product (m/z 268) of deoxySa. Highlighted is the distinctive fragment for 1-deoxySa at 
m/z 44. 
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4.3.4 Biosynthesis of 1-DeoxySa from [13C]Alanine by SPT 
 Because myriocin blocked the formation of 1-deoxySa in FB1-treated cells (Fig. 
4.2), it is possible that this compound arises from the condensation of L-alanine with 
palmitoyl-CoA by SPT as illustrated in Fig. 4.5. To test this hypothesis, proliferating 
cultures of Vero cells were grown in medium supplemented with varying ratios of natural 
abundance and L-[U-13C]alanine and L-[U-13C]serine. Vero cells were chosen for this 
experiment because they produced easily detectable levels of the deoxySa in control 
cultures and were somewhat more resistant to the growth inhibitory effects of FB1 in 
short term assays compared with the LLC-PK1 cells (in addition, culture medium without 
serine or alanine is also available commercially for these cells). The appearance of stable 
isotope-labeled 1-deoxySa and Sa were monitored by MS analysis of the products that 
have been produced from these precursors by the M+2 isotope shift (since one 13C of 
each amino acid is lost as 13CO2 in the condensation reaction). The experiment was 
designed with addition of both precursors because serine and alanine can be 
metabolically interconverted (albeit, with many intermediate steps) as well as 
incorporated into the co-substrate palmitoyl-CoA. Therefore, addition of the unlabeled 
amino acid should diminish the contribution from such 13C-labeled metabolites. 
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Figure 4.5. Structures of Sa and 1-deoxySa and a scheme for the biosynthesis of 1-
deoxySa and its accumulation in cells exposed to FB1. Also shown are the known sites of 
inhibition by FB1 and myriocin. 
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 As shown in Fig. 4.6A, essentially none of the L-[U-13C]serine was incorporated 
into 1-deoxySa but was preferentially incorporated into [13C]Sa (d18:0) and [13C]Sa1P 
(d18:0-P) (Fig. 6A). Conversely, L-[U-13C]alanine was preferentially incorporated into 
13C-labeled 1-deoxySa (m18:0) (Fig. 4.6B) versus Sa and Sa1P. 
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Figure 4.6. Incorporation of L-[U-13C]alanine (A) and L-[U-13C]serine precursors (B) 
into the 1-deoxySa (m18:0), Sa (d18:0), and Sa1P (d18:0-P) in Vero cells treated with 35 
µM FB1 for 48 h and grown in medium containing increasing concentrations of either L-
[U-13C]alanine- or L-[U-13C]serine(100 µM to 500 µM).  
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 The utilization of L-alanine by SPT is surprising, although there has been a recent 
report of 1-deoxySa in Hek293 cells that express the mutant form of SPTLC1 that is 
found in human sensory neuropathy type 1 (HSN1) as well as in lymphoblast lines 
derived from HSN1 patients (33). Therefore, to determine if SPT is responsible for 1-
deoxySa biosynthesis in these cells, the incorporation of [U-13C]palmitate into the 
sphingoid base backbones of sphingolipids and 1-deoxySa was analyzed using LY-B 
cells, a mutant Chinese hamster ovary (CHO) cell line with undetectable SPT activity due 
to mutation of the SPT1 subunit (21). As shown in Fig. 4.7, there was no detectable 
incorporation of 13C-label into 1-deoxySa by LY-B cells with or without addition of FB1 
(panel A), but when LY-B-LCB1 cells were used (which have restoration of SPT activity 
by stable transfection with the cDNA for SPT1), there is a low but detectable 
incorporation of [13C]palmitate into 1-deoxySa in these cells and robust biosynthesis and 
accumulation of 1-[13C]deoxySa when the cells were treated with FB1 (Fig. 4.7, panel A). 
 In addition, there was essentially no biosynthesis of Cer or N-acyl-1-deoxySa (1-
deoxyDHCer) in LY-B cells (the first two rows of all of the graphs in Fig. 4.7, panel B). 
In contrast, LY-B-LCB1 cells incorporated [13C]palmitate into the sphingoid base 
backbone (labeled 13C-base in Fig. 4.7B) and into both the sphingoid base and fatty acid 
(labeled 13C-base and fatty acid in Fig. 4.7B) of Cer (upper two graphs of Fig. 4.7B) and 
1-deoxyDHCer (lower two graphs of Fig. 4.7B). In addition, FB1 decreased the formation 
of these compounds, consistent with the accumulation of free 1-deoxySa (Fig. 4.7A). In 
this experiment, 1-deoxyDHCer was not a minor species because when all of the 
subspecies are summed, the amount of 1-[13C]deoxyDHCer is about one-third of the 
amount of [13C]Cer. However, the kinetics of Cer metabolism may be quite different 
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because 1-deoxyDHCer cannot undergo head group addition. Future studies will need to 
compare the relative rates of the two arms of the pathway. Nonetheless, all in all, these 
results establish that the formation of 1-deoxySa requires SPT, and when formed, most 
appears to be acylated unless FB1 is present. 
 
 141
 
Figure 4.7. Absence of 1-deoxySa biosynthesis by LY-B cells and restoration of its 
formation in LY-B-LCB1 cells.  
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4.3.5 Endogenous 1-DeoxyDHCer and Acylation of Exogenously Added 1-DeoxySa 
in LLC-PK1 Cells 
 The results with the LY-B and LY-B-LCB1 cells (Fig. 4.7) suggest that the 
accumulation of 1-deoxySa in LLC-PK1 cells treated with FB1 is due to interruption of 
the formation of endogenous 1-deoxyDHCer. To test this prediction, the amounts and 
types of 1-deoxyDHCer and Cer of LLC-PK1 cells were analyzed by LC-ESI-MS/MS. As 
shown in Fig. 4.8A, control (no addition) LLC-PK1 cells contain on average 32 ± 4 pmol 
of 1-deoxyDHCer/mg protein that are distributed among a variety of fatty acyl chain 
lengths that are similar to that of the Cer in the cells (Fig. 4.8B). In addition, when the 
cells were treated with 10 µM 1-deoxySa and analyzed after 48 h, they contained highly 
elevated amounts of 1-deoxyDHCer (4,630 ± 396 pmol/mg protein) that were ~90% 
suppressed if the cells were also treated with 50 µM FB1 (Fig. 4.8A). The addition of 10 
µM 1-deoxySa did not appear to have any effect on the amount of ceramide (in contrast 
the FB1 alone or in combination with 1-deoxySa caused a major suppression of Cer 
accumulation (Fig. 4.8B). Therefore, the findings with LLC-PK1 cells were similar to 
what was observed with the LY-B-LCB1 cells, i.e. it appears that cells make a substantial 
amount of 1-deoxySa that is acylated to 1-deoxyDHCer. 
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Figure 4.8. Endogenous N-acyl-sphingoid bases in LLC-PK1 cells and after incubation of 
the cells with exogenously added 1-deoxySa with or without FB1. 
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4.3.6 Cytotoxicity of 1-DeoxySa 
 The toxicity of free sphingoid bases (typically added to cells as the complex with 
BSA) is well known (13, 34), and has been demonstrated previously in LLC-PK1 cells as 
a model for FB toxicity (13). The effect of 1-deoxySa on these cells was determined 
using the chemically synthesized compound as the BSA complex (Fig. 4.9A) versus the 
effect of a Sa-BSA complex. Both compounds are equally cytotoxic both in terms of 
decreased cell growth and an increased number of detached-dead cells based on their 
inability to exclude trypan blue (Fig. 4.9A, inset). Because 1-deoxySa has been reported 
to be cytotoxic for cancer cell lines (34), we also examined its effect on the human 
prostate cancer cell line DU-145 using the WST-1 cell proliferation assay. As shown in 
Fig. 4.9B, 1-deoxySa was several fold more potent (IC50 ~ 2 µM) than Sa (IC50 ~ 7 µM) 
for this cancer cell line. 
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Figure 4.9. Effects of 1-deoxySa on LLC-PK1 and DU-145 cells.  
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 Analysis of the amounts of Sa, Sa1P, and 1-deoxySa in the LLC-PK1 cells treated 
with the 10 µM Sa (labeled d18:0 in Fig. 4.10, A–C) revealed that although there was a 
significant increase in intracellular Sa (Fig. 4.10A) compared with the control, the species 
that was present in the highest amount (~4 nmol/mg protein, a 27-fold increase) was 
Sa1P (Fig. 4.10B), indicating that a large fraction of added Sa undergoes phosphorylation. 
1-DeoxySa was also easily detected in the cells exposed to 10 µM 1-deoxySa (labeled 
m18:0 in Fig. 4.10C), and the amount was similar to the Sa in Sa-treated cells (~0.2 
nmol/mg protein, Fig. 4.10, A and C). 1-DeoxySa was not detected in the control cells 
(nor cells treated with Sa), nor was it phosphorylated (data not shown), which is expected 
since sphingosine kinase adds a phosphate to the hydroxyl group at carbon position 1. 
 Co-administration of Sa and FB1 caused large increases in Sa1P versus those 
obtained with addition of Sa or FB1 alone (Fig. 4.10, B and E); in contrast, the cellular 
amounts of Sa, while highly elevated, were not significantly different (Fig. 4.10D). 
Treatment with FB1 alone or FB1 plus 10 µM Sa caused a small but significant elevation 
in 1-deoxySa compared with the control (labeled none); however, co-administration of 1-
deoxySa and FB1 caused a ~25-fold elevation in 1-deoxySa compared with treatment 
with only 1-deoxySa or FB1 alone (Fig. 4.10, F and C). This provides further evidence 
that cells have a large capacity to acylate exogenous as well as endogenous 1-deoxySa. 
This was also evident in the large increase in 1-deoxyDHCer when 1-deoxySa was added 
to the cells (Fig. 4.10H). 
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Figure 4.10. Accumulation of Sa (A and D), Sa1P (B and E), 1-deoxySa (C and F), and 
decrease in ceramide (G) and change in 1-deoxydihydroceramide (H) levels in LLC-PK1 
cells treated as described in Fig. 4. 9 but only at the 10 µM concentration of Sa and 1-
deoxySa (A–C) or in combination with 50 µM FB1 (D–F).  
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4.3.7 Analysis of 1-DeoxySa in Liver and Kidneys of Mice Fed FB1 
 To determine if 1-deoxySa is elevated in the target organs for FB toxicity (liver 
and kidney for mice) (35), male P53N5-W mice were fed 50 ppm FB1 in a modified AIN-
76A diet for 6 months, and then lipid extracts from the livers and kidneys were analyzed 
by LC-ESI-MS/MS (Fig. 4.11). These analyses showed the typical elevation of Sa by FB1 
treatment for both organs (34), as well as the presence of substantial amounts of 1-
deoxySa in the FB1-fed mice, with the highest amount in liver. Given the similarity in the 
amounts of Sa and 1-deoxySa in liver, it is feasible that both compounds contribute to the 
toxicity of FB for this organ. 
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Figure 4.11. Accumulation of Sa (d18:0, black bars) and 1-deoxySa (m18:0, gray bars) 
in liver (upper) and kidneys (lower) of male P53N5-W mice fed a modified AIN-76A 
diet containing 0 ppm (Control) or 50 ppm FB1 for 6 months. 
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4.3.8 Validation of LC ESI-MS/MS Conditions for N-Acyl-1-Deoxysphinganine 
  
Up to this point in the studies, we have assumed that the acyl chain-length 
dependence of the ion yields for N-acyl-1-deoxysphinganines is similar to that for other 
dihydroceramides; however, this assumption should be validated before further studies 
are performed.  To do so, C16:0- and C24:0-1-deoxyDHCer were synthesized (41.42) 
and examined by LC ESI-MS/MS to determine how the ionization parameters for the 
MRM pairs for these N-acyl-1-deoxySa are similar or different than the corresponding 
Cers. As the alkyl chain length increases, it will usually be increasingly difficult to 
fragment the compound (i.e., higher eV must be applied, see Tables 4.1), hence, varying 
the eV as larger N-acyl-sphingoid bases are being analyzed, for this example, the 
collision energies that produce the same signal for C12:0-Cer and C24:0-Cer are 35 eV 
and 50 eV, respectively. Because Cer and 1-deoxyDHCer showed a similar ionization 
efficiencies, the precursor/product ion m/z’s and associated parameters for MRM 
detection of individual molecular species of 1-desoxymethyldihydroceramide (1-
desoxyMeDHCer) were applied by Cer and 1-deoxyDHCer parameters. However, the 
parameters for 1-desoxyMeDHCer should be confirmed or optimized using standards in 
the future study. 
Using these conditions, standard curves for these N-acyl-1-deoxySa were 
obtained by graphing the integrated ion intensities for these analytes, the corresponding 
ceramides and C12-Cer, since it is available as an internal standard for sphingolipid 
quantitation (from Avanti Polar Lipids).  Using optimized LC and ionization parameters, 
all of the subspecies displayed a linear signal response from 0.5 to 500 pmol, with little 
difference in cps due to the length of the fatty acyl-chain. The similarity in signal 
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response across all these chain lengths and for both Cer and 1-deoxyDHCer allows the 
C12:0 internal standard to be used for these species. 
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Table 4.1. API 3000 Mass Spectrometer Settings for ceramide, 1-
deoxydihydrceramide and 1-desoxymethyldihydroceramide 
 N-Acyl Precursor 
ion m/z 
Product 
ion m/z 
DP (V) FP(V) CE (V) 
Cer (d18:1)       
 C12:0 486.6 264.4 40 220 35 
 C16:0 538.7 264.4 40 220 40 
 C18:0 566.7 264.4 40 220 42.5 
 C20:0 594.7 264.4 40 220 45 
 C22:0 622.8 264.4 40 220 47.5 
 C24:1 648.9 264.4 40 220 50 
 C24:0 650.9 264.4 40 220 50 
 C26:1 676.9 264.4 40 220 50 
 C26:0 678.9 264.4 40 220 50 
1-DeoxyDHCer 
(m18:0) 
      
 C16:0 524.7 268.4 40 220 40 
 C18:0 552.7 268.4 40 220 42.5 
 C20:0 580.7 268.4 40 220 45 
 C22:0 608.8 268.4 40 220 47.5 
 C24:1 634.9 268.4 40 220 50 
 C24:0 626.9 268.4 40 220 50 
 C26:1 662.9 268.4 40 220 50 
 C26:0 664.9 268.4 40 220 50 
1-
DesoxyMeDHCer 
(m18:0) 
      
 C16:0 510.7 254.3 40 220 40 
 C18:0 538.7 254.3 40 220 42.5 
 C20:0 566.7 254.3 40 220 45 
 C22:0 594.8 254.3 40 220 47.5 
 C24:1 620.9 254.3 40 220 50 
 C24:0 622.9 254.3 40 220 50 
 C26:1 648.9 254.3 40 220 50 
 C26:0 650.9 254.3 40 220 50 
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Figure 4.12. Signal response for ceramides using LC ESI-MS/MS.  
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Figure 4.13. Signal response for 1-deoxydihydroceramides using LC ESI-MS/MS.  
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4.3.9 Re-examination of the Biosynthesis of Novel Sphingoid Bases upon 
Supplementation of the Culture Medium with Different Amino Acids 
 Since serine palmitoyltransferase is able to utilize L-alanine in addition to L-
serine, it is possible that it can also utilize the smaller amino acid glycine.  To investigate 
this hypothesis, RAW 264.7 cells were incubated with 10 mM of these three amino acids 
(individually) for 24 hr and the respective sphingoid bases were analyzed by LC ESI-
MS/MS; 10 µM FB1 was included in the incubation to inhibit acylation since that would 
necessitate the measurement of a large number of downstream metabolites and the goal 
of this study was to detect the sphingoid bases per se.  As shown in Fig. 4.14 are elution 
profiles for the MRM pairs for sphinganine and 1-deoxySa and the predicted MRM pair 
for 1-desoxymethylsphinganine (1-desoxyMeSa) from a reverse phase column (note that 
the 1-deoxy sphingoid bases were analyzed as described in “Experimental procedures”, 
but with the additional MRM pair of m/z  272.3/254.2 for 1-desoxyMeSa in Fig. 4.14D;  
the elution times were 2.6 min for Sa, 2.7 min for 1-desoxyMeSa and 2.8 min for 1-
deoxySa, with all having baseline resolution.).  It is evident from these results that the 
assignments of the sphingoid bases based on these MRM pairs not only agree with the 
order of elution from the column (i.e., for sphinganine to be most polar and elute first, 
followed by 1-desoxyMeSa, then 1-deoxySa) but also by the relative abundance of the 
fragment ions relative to the amino acids that has been added (e.g., 1-desoxyMeSa is 
higher with glycine supplementation, etc.). Thus, these LC ESI-MS/MS results further 
validate our hypothesis that L-serine (Fig. 4.14A), L-alanine (Fig. 4.14A B) and L-
glycine (Fig. 4.14A C) are incorporated into the Sa, 1-deoxySa, and 1- 1-desoxyMeSa.  
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 A number of other amino acid were also examined because they might also be 
envisioned to be utilized by serine palmitoyltransferase if the active site has room to 
accommodate an additional methylene (threonine and valine) or larger moieties (leucine 
and isoleucine).  Because there are no standards for the predicted condensation products, 
it was assumed that at least one of the prevalent fragments would be the dehydration 
product, so the LC ESI-MS/MS analysis used MRM pairs for the intact parent ion and the 
dehydration product.  None of these additions produced an increase in ion abundance at 
the respective MRM pair, therefore, it appears unlikely that these additional amino acids 
are utilized to produce additional categories of alternative sphingoid bases. 
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Figure 4.14 Re-examination of the biosynthesis of novel sphingoid bases upon 
supplementation of the culture medium with different amino acids. This is a plot of the 
relative ion abundance of the shown selected MRM pairs (D) at different elution times 
from reverse phase LC (Supelco 2.1 X 50 mm Discovery C18 column, Sigma) column. 
L-serine (A), L-alanine (B) and L-glycine (C) (each has 10 mM concentration) were 
supplemented in RAW 264.7 cells. (D) The structures of sphingoid bases and their 
fragmentations. 
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Figure 4.14 Re-examination of the biosynthesis of novel sphingoid bases upon 
supplementation of the culture medium with different amino acids (Continued). This is a 
plot of the relative ion abundance of the shown selected MRM pairs (D) at different 
elution times from reverse phase LC (Supelco 2.1 X 50 mm Discovery C18 column, 
Sigma) column. L-serine (A), L-alanine (B) and L-glycine (C) (each has 10 mM 
concentration) were supplemented in RAW 264.7 cells. (D) The structures of sphingoid 
bases and their fragmentations. 
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Table 4.2. ABI 4000 Mass Spectrometer Settings for Long Chain Bases and 1-deoxy-
sphingoid bases 
 Precursor ion 
m/z
Product ion 
m/z
DP (V) CE(V) CXP (V)
d17:1 So 286.4 268.3 40 15 15 
d17:0 Sa 288.4 60.0 50 45 9 
d18:1 So 300.4 282.4 40 19 16 
d18:0 Sa 302.4 60.0 50 45 10 
m18:0 1-DeoxySa 286.4 268.4 80 30 15 
m17:0 1-DesoxyMeSa 272.3 254.2 70 20 15 
      
4.3.10 The Types and Amounts of the Sphingoid Bases that Are Produced by Can 
Be Affected Substantially by Amino Acid Supplementation 
 In addition to determining if these three categories of sphingoid bases could be 
made by mammalian cells, we were interested in knowing if supplementation with one 
type would both increase the amounts of the respective sphingoid base and decrease the 
amounts of the alternatives—as would be predicted from them being made by a single 
enzyme.  To conduct these studies, a stable isotope precursor was used to allow the newly 
made sphingoid bases to be distinguished from ones already in the cells, and [U-
13C]palmitate was selected because it is incorporated into all three types of sphingoid 
bases.  As before, the products were analyzed by LC ESI-MS/MS and the cells that were 
selected for the experiment were a SPT1/2 cell line, which is derived from HEK293 cells 
that are stably overexpressing both of the subunits of serine palmitoyltransferase (SPT1 
and SPT2) (as described in J. Wei et al., in press).   These experiments did not include 
FB1 to block acylation because we were interested to see how the relative amounts of the 
downstream metabolites were also affected. 
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 As shown in Fig. 4.15A, under basal conditions the amount of free [13C]-Sa is 
very low, but detectable.  As predicted addition of serine caused a large increase, 
although the SD was high (perhaps because Sa is also converted to Sa1P, and we did not 
control carefully for the possibility that this metabolite might turn over during the 
scraping of the cells before lipid extraction, etc).  Interestingly, addition of both alanine 
and glycine caused increased [13C]Sa—which is not surprising for glycine since it can be 
converted to serine by serine hydroxymethyltransferase.   
 In a similar way, a small amount of [13C]1-deoxySa was produced when the cells 
were in control medium (ca. 4 pmol/mg protein), and the amount increased substantially 
ca. 10-fold  upon alanine supplementation (Fig. 4.15B).  It was also interesting that the 
production of [13C]1-deoxySa was reduced when the cell medium was supplemented with 
serine or glycine (Fig. 4.15B). The amounts of [13C]1-desoxyMeSa were below detection 
(estimated to be ~0 pmol/mg protein) in cells in control medium (and medium 
supplemented with serine or alanine), but increased substantially when glycine was added 
(Fig 4.15C). 
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Figure 4.15. Evaluation of the biosynthesis of novel sphingoid bases upon 
supplementation of the culture medium with different amino acids. L-serine (A), L-
alanine (B) and L-glycine (C) (each has 10 mM concentration) were supplemented with 
[U-13C]palmitate in SPT 1/2 cells. 
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Figure 4.15. Evaluation of the biosynthesis of novel sphingoid bases upon 
supplementation of the culture medium with different amino acids (Continued). L-serine 
(A), L-alanine (B) and L-glycine (C) (each has 10 mM concentration) were supplemented 
with [U-13C]palmitate in SPT 1/2 cells. 
 
 The types and amounts of N-acyl-metabolites were affected similarly.  In these 
analyses, there are two categories of compounds that have been made from [13C]palmitate, 
one group where the stable isotope was incorporated into the sphingoid base backbone 
but the N-acyl fatty acid did not contain 13C (labeled 13C-base in Fig. 4.16), and the other 
where both the sphingoid base and fatty acid contain 13C (labeled 13C-base and fatty acid 
in Fig. 4.17).  The species with a sphinganine backbone are shown in the upper two 
graphs of Fig. 4.16 and 4.17, the ones for 1-deoxySa are in the middle two graphs of Fig. 
4.16 and 4.17, and  for 1-desoxyMeSa, the lower two graphs of Fig. 4.16 and 4.17. Serine 
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addition led increased the formation of [13C]Cer compounds; alanine addition elevated 
[13C]1-deoxyDHCers; and glycine addition elevated [13C]1-desoxymethylDHCers. The 
apparent elevation of 13C-labeled 1-desoxyMeDHCer upon alanine supplementation is 
likely to be an artifact because the MRM for the 13C-labeled 1-desoxyMeDHCer shares 
with [13C]1-deoxyDHCer. Therefore LC ESI-MS/MS conditions for 1-desoxyMeDHCer 
and its 13C-labeled forms should be improved. One of the additionally interesting 
observations from this experiment is that the chain length subspecies for 1-deoxyDHCer 
are predominately C18, C22, C24:1 and C24 subspecies (not C16, as often seen with 
sphinganine), which might indicate that this compound is better utilized by CerS1 and/or 
CerS2, which are responsible for forming those categories of ceramides (43-45). 
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Figure 4.16. N-acyl-sphingoid base biosynthesis by SPT1/2 cells with amino acid 
supplementations. L-serine, L-alanine and L-glycine (each has 10 mM concentration) 
were incorporated [13C]palmitate into the sphingoid base backbone (labeled 13C-base ). 
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Figure 4.17. N-acyl-sphingoid base biosynthesis by SPT1/2 cells with amino acid 
supplementations. L-serine, L-alanine and L-glycine (each has 10 mM concentration) 
were incorporated into both the sphingoid base and fatty acid (labeled 13C-base and fatty 
acid). 
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4.3.11 Analysis of 1-DeoxySa in SPT1/2 cells with Knock Down of Serine 
Metabolism 
 Serine, a non-essential amino acid, is a necessary precursor for the synthesis of 
various biomolecules, for examples, proteins, amino acids, phosphatidylserine, 
sphingolipids, nucleotides, etc., which are important for cellular and tissue functions. 
Serine is derived from three sources—extracellular uptake, methylation of glycine by 
serine hydroxymetholtransferase, and de novo biosynthesis.  The de novo pathway begins 
with the glycolysis intermediate 3-phosphoglycerate (46) which is oxidized by 3-
phosphoglycerate dehydrogenase (PHGDH) to 3-phosphohydroxypyruvate (3-P-
hydroxypyruvate) (47) that is converted to 3-phosphoserine (3-P-serine) by 
phosphoserine aminotransferase, and finally, 3-Phosphoserine phosphatase (PSPH) 
removes the 3-P-seine to yield seine.  All of these sources are physiologically relevant, 
including the de novo pathway, which is known to be defective in a number of genetic 
diseases (46, 47). Therefore, since we had noted that varying the extracellularly provided 
amino acid could affect the type of sphingoid bases that were made, we also examined 
one of the pathways for endogenous modulation—the de novo biosynthesis pathway. 
 In these preliminary experiments, SPT1/2 cells were treated with siRNA against 
3-phosphoglycerate dehydrogenase (PHGDH) and 3-phosphoserine phosphatase (PSPH) 
(as well as the matched nonspecific siRNA control) for 72 hr followed by labeling of the 
sphingoid bases by [U-13C]palmitate in medium that contained FB1 and either no Ser and 
Gly or these amino acids supplemented to 0.25 mM (Fig.4.18). The prediction of this 
pilot experiment was that knockdown of serine biosynthesis would elevate biosynthesis 
of the alternative sphingoid bases because their precursors would still be present, and 
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indeed, there was an elevation in [13C]1-deoxySa (Fig.4.18). Thus, although this needs to 
be studied further to confirm knock down of these enzymes of serine metabolism by 
Western blotting and/or amino acid analysis, this experiment indicates that one of the 
previously unanticipated consequences of abnormal serine metabolism might be the 
production of these novel sphingoid bases. 
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Figure 4.18. Effect of double knockdown by 3-phosphoglycerate dehydrogenase 
(PHGDH) and 3-Phosphoserine phosphatase (PSPH) siRNAs on 1-deoxySa synthesis. 
Shown are the amounts of 1-[13C]deoxySa that are produced by SPT1/2 cells.  
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4.4 Discussion 
 These studies have established that the mystery peak that we described in FB- 
treated cells almost a decade ago (20) is 1-deoxySa, a novel sphingoid base that is 
biosynthesized by SPT via the condensation of palmitoyl-CoA with L-alanine. It is 
surprising that this compound has not been more widely noted in mammalian cells; 
however, its presence as mainly the N-acyl derivatives makes it difficult to detect in the 
much larger pool of cellular Cer and other neutral lipids. 
 This compound and other 1-deoxysphingoid bases are known to be made by other 
organisms (36), but have only recently surfaced in mammalian cells in studies of a 
mutation in the SPTLC1 gene that causes HSN1 (33). However, because our studies have 
found substantial amounts of these compounds in mammalian cell lines not thought to 
have a defect in SPT, it is evident that 1-deoxySa and 1-deoxyceramides are normally 
made by mammals. This does not rule out the possibility that abnormal elevations in 1-
deoxySa by a mutant SPTLC1, or due to inhibition of its acylation by FB, could cause 
cytotoxicity. 
 The rapid and extensive acylation of 1-deoxySa is not surprising since studies of 
the structural requirements of sphingoid bases as substrates and inhibitors of CerS had 
previously shown that this compound was acylated (37). Although very long chain 1-
Deoxy-DHCer will be synthesized and optimized for the ionization and fragmentation 
conditions, we built the methods for the analysis of 1-deoxySa and 1-deoxyDHCer by LC 
ESI-MS/MS. In LYB-LCB1 cells FB1 caused a much larger increase in 1-deoxySa (40 
pmol/mg protein) than can be accounted for solely by the levels of 1-deoxyDHCer in the 
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untreated cells. The precise fate of 1-deoxySa is not known and raises interesting 
questions about the subsequent metabolism and functions of these compounds since 1-
deoxyDHCer might be desaturated to 1-deoxyceramides, but none of the usual 
downstream complex sphingolipids (sphingomyelins, ceramide 1-phosphates or 
hexosylceramides) can be made. Furthermore, the free sphingoid base cannot undergo 
phosphorylation, which is a prerequisite step for catabolism of So and Sa via S1P lyase 
(38). Therefore, there must be alternative mechanisms for elimination of this category of 
sphingoid bases that are not yet understood. 
 The cytotoxicity of 1-deoxySa is similar to that previously seen for sphingoid 
bases (39), although the findings with DU-145 cells indicate that removal of the 1-
hydroxyl group has enhanced the potency somewhat. It is possible that some of the 
biological effects of 1-deoxySa occur after its metabolism to 1-deoxyDHCer, or due to 
interference with the metabolism of another sphingolipid, such as by inhibition of 
sphingosine kinase. However, the finding that addition of 1-deoxySa to LLC-PK1 cells 
did not decrease the ability of FB1 to elevate Sa1P (Fig. 4.10E) indicates that it does not 
eliminate sphingoid base phosphorylation, although its effects might be more pronounced 
under other circumstances.  
 The high amounts of 1-deoxysphingolipids in liver versus kidney (Fig. 4.11) is 
reminiscent of the greater sensitivity of liver to FB1-induced toxicity in mice (3).We have 
analyzed a number of tissues from other fumonisin-treated animals, such as liver and 
kidneys from Sprague-Dawley rats, several strains of mice and pigs (data not shown), and, 
so far, the highest amounts of 1-deoxySa and 1-deoxyDHCer have been found in P53N5 
mice. It would be interesting to know if this species, which was derived originally from 
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the C57BL/6 mouse, has structural differences in SPT that cause it to produce higher 
amounts of 1-deoxySa, in analogy to the HSN1 mutation (33). 
 We have noted also that the appearance of 1-deoxySa in cells in culture increases 
with the length of time that they have been left in culture (Figs. 4.2 and 4.3). This might 
be related to whether or not they are growing because we have not noted significant 
amounts in rapidly proliferating LLC-PK1 cells (8, 13), whereas, confluent cultures of 
LLC-PK1 cells left in medium for several days have amounts of 1-deoxySa that approach 
the levels of Sa (Figs. 4.2 and 4.3), and 1-deoxyCer that can be higher than Cer (Fig. 4.8). 
To some extent, this is probably due to the lack of downstream metabolism of these 
compounds, but another factor might be greater formation of 1-deoxySa after the medium 
and cells become depleted of serine relative to alanine. Indeed, we were easily able to 
detect 1-deoxySa in Vero cells even without treatment with FB1 (data not shown), and 
Vero cells are known to rapidly deplete serine from culture medium (40). This issue led 
us to think about the possible participation of amino acid supply in the types of sphingoid 
bases that are made by cells. 
 Examination of the composition of the cell culture medium for the HEK293 and 
SPT1/2 cells (Dulbecco's Modified Eagle Medium: Nutrient Mixture F-12, DMEM/F12), 
we note that serine and glycine have been added at concentrations that are 5-fold higher 
than alanine.  Thus, it is not surprising that the production of 1-deoxySa has not been 
noticed previously. 
 The availability of serine over alanine is not always encountered in vivo, however.  
As shown in Fig. 4.19, serine metabolism in animal cells has been well characterized (46) 
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and although the biosynthetic enzymes are widely distributed, the amounts are known to 
vary—for example being significantly upregulated in proliferating cells and neoplastic 
tissues (48). The phosphorylated pathway is considered to play a chief role in the de novo 
synthesis in various mammalian cells, and its physiological importance has been 
evidenced in inherited PHGDH deficiency. Patients with this deficiency have reduced 
enzyme activities and exhibit marked decreases of serine and glycine concentrations in 
both plasma and cerebrospinal fluid (49, 50). Consequently, they are afflicted with severe 
neurological disorders.  
 Thus, since we have shown that 1-DeoxySa and its N-acyl-derivatives are 
elevated in alanine supplemented medium (Fig. 4.15, 4.16, and 4.17) and—it appears—
when biosynthesis was suppressed by siRNAs (Fig. 4.18), this suggests strongly that 
these compounds will be elevated in some physiologic or pathophysiologic states.  Since 
sphingoid bases are highly bioactive compounds (36), they may be mediators of human 
diseases. 
 It is possible that there are additional factors that affect the amino acid selectivity 
of SPT in vivo.  Inuzuka et al. (51) have reported that Serinc, “named for being a “serine 
incorporator”, facilitates the incorporation of serine into membrane lipids by facilitating 
the synthesis of phosphatidylserine and sphingolipids. Serinc proteins are found in ER 
membranes, and it has been proposed that they bind directly to SPT, perhaps linking 
sphingolipid biosynthesis to a serine synthetic enzyme, such as PHDGH. There are 
several isoforms, and Serinc1-5 and Serinc2 and Serinc5 were reported to significantly 
enhance the SPT activity in mammalian cells. Because the membrane topology of Serinc, 
which contains 11 transmembrane segments similar to amino acid transporters, the 
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authors have speculated that Serinc may function by carrying a serine molecule into the 
hydrophobic milieu of membrane lipid bilayers, which is responsible for efficient 
reactions occurring among serine, hydrocarbon tails, and lipid synthetic enzymes. 
 Thus, one can envision how SPT might serve as a sensor for changes in the ratios 
of serine and alanine by producing alternative categories of sphingoid bases with 
different metabolic fates, effects on membrane structure, cell signaling (52), and (or) 
interaction with nuclear receptors that bind sphingosine (53). 
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Figure 4.19 The speculation of correlation between amino acid synthesis and sphingolipid 
biosynthesis. There are two known serine disorder deficiencies, such as 3-
phosphoglycerate dehydrogenase (PHGDH) deficiency and 3-phosphoserine phosphatase 
(PSPH). In Serine deficiency disorder, the increased alanine might cause 1-deoxy SL 
biosynthesis.
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CHAPTER 5 
    CONCLUSIONS  
This thesis describes Cer biosynthesis by mouse embryonic stem cells and 
embryoid bodies by transcript profiling and metabolomic analysis (i.e. determining 
transcript levels for enzymes involved in Cer biosynthesis by qRT-PCR and respective 
metabolites by liquid chromatography-electrospray ionization tandem mass spectrometry, 
LC-ESI MS/MS).  And, this focused genomic and metabolomic investigation has 
uncovered changes in expression of Cer synthases, fatty acyl-CoA elongases, fatty acyl-
CoA’s and Cer subspecies that are in reasonable agreement, and which might reflect 
important events that occur during embryogenesis. 
Mammalian CerS2 was also characterized and revealed that CerS2 mRNA is 
found at the highest level of all CerS by qRT-PCR analysis and has the broadest tissue 
distribution by LC ESI-MS/MS analysis. CerS2 has a remarkable acyl-CoA specificity, 
showing no activity using C16:0-CoA and very low activity using C18:0, rather utilizing 
longer acyl-chain CoAs (C22–C24) for ceramide synthesis. There is a good correlation 
between CerS2 mRNA levels and levels of ceramide and sphingomyelin containing long 
acyl chains, at least in tissues where CerS2 mRNA is expressed at high levels. These 
results indicate significant and unexpected biological and biochemical differences 
between the CerS genes and proteins, and imply a unique role for CerS2. 
Serine palmitoyltransferase (SPT) utilize serine and palmitoyl-CoA as substrates 
to produce sphinganine (Sa) by sphingolipid de novo biosynthesis. Sa is acylated to 
(dihydro)ceramides containing different fatty acyl chains. In this thesis, I describe that 
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SPT also exploit alanine instead of serine to generate a novel sphingoid base, 1-
deoxysphinganine (1-deoxySa) and its 1-deoxydihydrocermides. 1-DeoxySa was isolated 
from the North Arctic clam Spisula polynyma (1) and disrupts actin stress fibers through 
the inactivation of Rho (1) and has been suggested to induce cell death in the prostate 
cancer cell lines via stimulation of the de novo synthesis of ceramide and protein kinase 
C ζ activation (2). This actin depolymerization might lead autophagy in mammalian cell 
lines. Serine and alanine might compete to be utilized by SPT catalytic site or these 
amino acids might be brought into play by several factors such as Serinc, serine 
transporter, etc.  
In summary, these findings are as regards the unappreciated category of 
sphingolipid, gene and their roles in mammalian system. Different amino acids are 
condensed with fatty acyl-CoA by serine palmitoyltransferase to produce 1-
deoxysphinganine and sphinganine. Those sphingoid bases are acylated to form N-acyl 
derivates by ceramide synthases. In Serine disorder deficiency, the accumulation of 
alanine might cause 1-deoxy sphingolipids by a deficiency of phosphorylated pathway 
enzymes and bring about toxicity. Another report from Hornemann (3) is that human 
sensory neuropathy type 1 patient has the higher amounts of 1-deoxysphinganine. 
Therefore, this novel category of sphingoid bases and its related genes might play 
important roles in cell regulation, development, especially in human diseases.  
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